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Abstract Page
Background: Hepatitis C Virus is considered to be a global public health threat because
seventy-five percent of infected persons have no symptoms and are unaware of their
infection. It is significant to note that AI/ANs commonly contend with issues that
prevent them from receiving or seeking medical care.
Objectives: The purpose of this study was to: (a) Characterize the level of depression,
alcohol consumption, stigma, and quality of life; (b) Examine the relationship among the
variables of age, gender, residing on an AI/AN reservation, current partner status,
depression, alcohol consumption, and stigma with quality of life in a sample of AI/ANs
living with HCV; and (c) Identify factors that explain the greatest amount of variance in
the quality of life.
Design: A descriptive, cross-sectional, correlational design with purposive sampling o f
101 AI/AN adults with HCV from the Southwestern U.S. was implemented.
Method: Instruments used to measure the influence o f variables include the Center for
Epidemiological Studies Depression scale, Alcohol Use Disorders Identification Test,
HCV Stigma Scale, and MOS SF-12v2 Quality of Life questionnaire.
Results: Correlational analysis indicated a statistically significant inverse relationship
between PCS and CES-D (r = -.438, p = .000); statistically significant positive
relationship between MCS and Age (r = .205, p = .04); statistically significant inverse
relationship between MCS and CES-D (r = -.726, p = .000); statistically significant
positive relationship between CES-D and AUDIT (r = .400, p = .000); CES-D and Stigma
(r = .485, p = .000). Regression analysis indicated the overall models significantly

predicts QOL - PCS and CES-D significantly contributed to the model; QOL - MCS and
CES-D and AUDIT significantly contributed to the model.
Implications: The identification of factors that influence QOL in HCV patients has the
potential to give direction to the development of nursing interventions or culturally based
care that may improve life quality in AI/AN persons living with HCV. This study will
help to determine the level of depression, alcohol consumption, stigma, and QOL among
AI/AN persons living with HCV. These findings have important implications for HCV
education, treatment, AI/AN health care policy and practice improvements.
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Chapter 1
Introduction

SIGNIFICANCE OF THE PROBLEM
Hepatitis C Virus (HCV) is considered to be a global public health threat.
Alarmingly, 75% of infected persons have no symptoms and are unaware o f their health
status. When symptoms do occur, they may be mild and indistinguishable from hepatitis
A or B viruses (Centers for Disease Control and Prevention (CDC), 2009a). According
to Wise, Bialek, Finelli, Bell, and Sorvillo (2008), the acute case fatality rate is low;
approximately 75% of infected persons suffer chronic illness. In addition to the physical
manifestations and complications, chronic HCV is also associated with neuropsychiatric
complaints, most notably fatigue and depression. Treatment is costly, causes difficult
side effects, but is effective in eliminating the virus and reducing liver injury in fewer
than 50% of diagnosed cases (The Indian Health Service [IHS] Provider, 2007).
Currently, there is no vaccine against HCV; however, in 1998, recommendations for the
prevention and control of HCV in high-risk groups were issued (CDC, 2001).
Despite the overall successes in the fight against viral hepatitis, disparities
continue to exist. It is significant to note that American Indian/Alaskan Natives
(AI/ANs) commonly contend with issues that prevent them from receiving or seeking
medical care. These issues include cultural barriers, geographic isolation, educational
level, and financial disparities (Jones, 2006). Some o f the leading diseases and causes of
1

2

death among AI/ANs are heart disease, cancer, unintentional injuries (accidents),
diabetes, and stroke (CDC, 2003). In addition, AI/ANs have a high prevalence and risk
factors for mental health, suicide, obesity, substance abuse, sudden infant death syndrome
(SIDS), teenage pregnancy, liver disease, and hepatitis (IHS, 2009; Shore & Manson,
1983).
In 2007, AI/ANs were twice as likely to develop a case of HCV, as compared to
the White population. In 2005, AI/ANs ages 40 years and over, were 70% more likely to
have Hepatitis B, than non-Hispanic Whites. The data on chronic Hepatitis B and HCV
infection (past or present) are not included by the CDC in the National Notifiable
Diseases Surveillance System reports, because they are undergoing data quality review.
This data is not reported in the CDC Healthy People 2010 database (Office of Minority
Health [OMH], 2009); the National Health and Nutrition Examination Surveys
(NHANES) do not include groups who may be considered at higher risk for hepatitis
infection (i.e., Indigenous people, those institutionalized or incarcerated, injection drug
using homeless populations, etc.). Therefore, the reported hepatitis data provide
conservative estimates of disease prevalence (McQuillan et al., 2010).
The HCV infection is one of the most important causes of chronic liver disease in
the U.S.. It accounts for about 15% of acute viral hepatitis, 60 to 70% o f chronic
hepatitis, and approximately 50% of cirrhosis, end-stage liver disease, and liver cancer
(Institute of Medicine [IOM], 2010a). Within the U.S. population, 1.6%, or an estimated
four million Americans, have antibody to HCV, indicating ongoing or previous infection
with the virus. The CDC (2009e) reports that hepatitis causes an estimated 15,000 deaths
annually in the U.S. Research conducted by Scott and Garland (2008) with aboriginal
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North Americans found that the route of transmission was similar to the general U.S.
population and included injection drug use and blood transfusion exposure. It is
important to also note that a well-defined and key characteristic of HCV is its tendency to
cause chronic liver disease; the liver injury can lead to cirrhosis, liver failure, and liver
cancer (Butt, McGinnis, Skanderson, & Justice, 2009).
Overall, the prevalence of acute HCV has declined substantially (from 5.2 cases
per 100,000 population in 1995 to 0.5 cases per 100,000 population in 2007) among
persons aged 25 - 39 years, the age group that historically maintained the highest rates of
infection (CDC, 2009c). Improvements have also been made in reducing disparities in
racial/ethnic-specific rates; during the years from 2004 - 2007 the incidence of acute
HCV was similar across all racial/ethnic populations with the exception of AI/ANs, for
whom rates were higher. Notably in 2007, rates were similar across racial/ethnic
populations other than AI/ANs, for whom the rate was 0.5 cases per 100,000 populations
(CDC, 2009d). Close monitoring of the incidence in at-risk communities remains critical
in the detection of the disparities (Smedley, Stith, & Nelson, 2003).
Wise and colleagues (2008) propose that disease burden and mortality from HCV
will increase in the U.S. in correlation to the increase in the numbers o f persons with
long-standing chronic infection increase. The mortality rates from 1995 - 2004 identified
a total of 56,409 hepatitis C-related deaths. This increase was greater among males
(144%) than females (81%), and among non-Hispanic blacks (170%) and AIs (241%)
compared to non-Hispanic whites (124%) and Hispanics (84%) (CDC, 2009a; National
Institute of Diabetes and Digestive and Kidney Diseases [NIDDK], 2006). Hepatitis C
virus is an important cause of premature mortality. Despite small declines in recent

years, rates have continued to increase among persons aged 5 5 -6 4 years. This clearly
supports the need for community-academic partnerships in research that addresses HCV
mortality as it continues to increase substantially since 1995 (Lesser & Oscos-Sanchez,
2007).
PURPOSE OF THE STUDY
The purpose of this study is twofold. First, it will examine the relationship
between quality of life (QOL), depression, alcohol consumption, and stigma in this
sample of AI/ANs living with HCV. A review of the literature revealed a need for more
quantitative research to examine the prevalence of depression in AI/ANs living with
HCV and compare the effects of their HCV status, stigma, alcohol consumption, and
depression on QOL dimensions. Second, this proposed study will fill a gap in the
hepatitis and nursing literature by describing QOL and variables of depression, alcohol
consumption, and stigma among AI/ANs living with HCV. The results of this study will
bring new knowledge within the context of AI/AN health and further the development a
culturally based frameworks useful in assisting AI/AN HCV patients and health care
providers (Giger & Davidhizar, 2007).
This is a public health priority because depression generally has been associated
with the outcomes of chronic diseases like HCV and has contributed to the high
economic burden of health care costs (Bailey et al., 2009; Kaiser Family Foundation,
2009). The economic burden o f HCV is directly related to the complications of cirrhosis
and hepatocellular carcinoma (HCC). Hospitalizations account for a large proportion of
the expenditures for HCV-related care. In 2004, approximately 419,000 hospital
discharges in the U.S. were attributed to liver disease due to HCV (Everheart, 2008). In
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1997, an estimated $1.8 billion in medical care costs was associated with HCV infections
(Leigh et al., 2001) while in 2011, the total healthcare cost associated with HCV infection
was $6.5 ($4.3-$8.2) billion (Razavi et al., 2013). Total cost is expected to peak in 2024
at $9.1 billion ($6.4-$ 13.3 billion). The majority of peak cost will be attributable to more
advanced liver diseases—decompensated cirrhosis (46%), compensated cirrhosis (20%),
and HCC (16%). The maximum cost associated with mild to moderate fibrosis (F0-F3)
occurred in 2007 at nearly $780 million. The cost associated with compensated cirrhosis
is expected to peak in 2022 at $1.9 billion, while the peak cost for decompensated
cirrhosis and HCC is predicted to occur in 2025, with annual costs in excess of $4.2
billion and $1.4 billion, respectively (Razavi, 2013).
Patients living with HCV have a significant decrease in their QOL,
although treatment success can alleviate this negative effect (Rodger, 1999). The
rate of depression amongst HCV patients (n = 157) was found to be 59%, resulting in a
significant reduction in health-related QOL (Gallegos-Orozco et al., 2003). The World
Health Organization (WHO, 2010) reports depression is the leading cause o f disability
worldwide; moreover, the risk of depression is greater for persons living with chronic
HCV and a common side effect due to HCV treatment medication.
Hepatitis C is associated with reduced health related QOL as reflected in
the disturbances o f behavioral, cognitive, physical, and social aspects o f w ell
being and, therefore, leads to physical and psychological problems. Quality o f life
has also been shown to decrease in patients recently made aware of their HCV status.
The reason for this decline in QOL seen after diagnosis, in the absence of treatment, may
be secondary to a labeling phenomenon (Rodger, 1999). Furthermore, persons with

HCV suffer from debilitating fatigue, pruritus, loss o f self-esteem , depression,
and complications of cirrhosis (Younossi, Boparai, McCormick, Price, & Guyatt,
2001).

Specific Aims:
Aim #1:

Characterize the level of depression, alcohol consumption, stigma,
and quality of life among a sample of AI/ANs living with HCV.

Aim #2:

Examine the relationship among the variables o f age, gender, residing
on an AI/AN reservation, current partner status, marital status,
depression, alcohol consumption, and stigma with quality of life in a
sample of AI/ANs living with HCV.

Aim #3:

Identify factors that explain the greatest amount of variance in the
quality of life of AI/ANs living with HCV.

CONCEPTUAL MODEL
The framework underlying this study is derived from the literature based on the
concepts of QOL, depression, alcohol consumption, and stigma (Figure 1). Living with a
HCV diagnosis can be a significant stressor for AI/AN persons and their families, social
support system, and communities (Whitbeck, Adams, Hoyt, & Chen, 2004). The
responsibilities and burden of living with HCV and its complications can lead to
reactions such as psychological stress, denial, anger, and even depression (Johnson,
Gryczynski, & Wiechelt, 2007; Neumeister et al., 2007). Over time, these responses may
be short-lived and some patients, invariably, learn to cope with HCV and life in general.
However, there may be some who experience prolonged and lingering feelings of stress
and depression and are unable to adapt to living with HCV. A potential explanation for
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the development of depressive symptoms based on the Transactional Model of Stress and
Coping, is that persons living with HCV cope differently than persons who do not
develop symptoms of depression, anger, or stress (Lazarus & Folkman, 1984).

M odel
Stigma
(Stigma Scale
modified)

Alcohol
Consumption
(AUDIT)

\

Quality!
^ of life

Demographic Variables
(Age, G ender Marital
status, Education,
Length of tim e w/
HCV, Comorbiditica,
Antiviral t> (interferon/
ribavirin)

(SF-12v2)|

Figure 1 Conceptual Model: QOL in AI/AN persons with HCV

Quality of Life - Short Form-12v2 (SF-12v2) - The Medical Outcomes Study
(MOS) began as a prospective, four-year observational study o f the influence of
characteristics of providers, patients, and health systems on outcomes of care. Since that
time, several measures of health status and QOL were developed and evaluated in this
study (Stewart, Hays, & Ware, 1988). The most widely used and best known is the SF36; it uses 36 items to cover eight dimensions: physical functioning, physically related
role limitations, social functioning, pain, vitality, mental health, emotionally related role
limitations, and general health perceptions. The SF-12v2 was adapted from this measure
For this study, the SF-12v2 (Appendix B) was applied to examine QOL in AI/AN HCV
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participants (Ware & Sherboume, 1992). The QOL of persons living with HCV has
become increasingly important. There is now a paradigm shift in transforming goal
therapy to improve QOL in addition to the reduction of symptoms, HCV suppression, and
extension of survival.
Center for Epidemiologic Studies-Depression (CES-D) scale - The CES-D was
developed by the CES at National Institute of Mental Health (NIMH) specifically to meet
the need for a brief, inexpensive measure of depression suitable for application in
community surveys (McDowell, 2006; Radloff, 1957). Cognitive problems, depression
being most common, is often overlooked in routine clinical encounters. This failure to
recognize this problem could influence treatment outcomes for persons living with HCV
(Horsmans, 2005). An awareness of depression’s prevalence among HCV persons and its
potential mechanisms will encourage both patient and health care providers to be
proactive in addressing depression affiliated with chronic HCV. The instrument is not
explicitly tied to a theoretical framework but can screen for clinical depression in large
epidemiological studies (Frank-Stromborg & Olsen, 1997).
Alcohol Use Disorders Identification Test (AUDIT) - There is no theoretical
framework that guides the AUDIT; however, this is a measure developed by the WHO as
a screening instrument for hazardous and harmful alcohol consumption (Saunders,
Aasland, Babor, de la Fuente, & Grant, 1993). The use of heavy alcohol consumption is
an important cofactor in the progression of HCV-related liver disease leading to cirrhosis
and HCC. Also, heavy alcohol consumption of more than 80 grams per day seriously
compromises HCV illness or treatment. The NIH (2002) reports safe levels of alcohol
consumption is unclear and that even moderate levels of consumption may accelerate
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HCV disease progression in some patients. Abstaining from alcohol is one of the most
important factors in preserving liver health in persons with HCV, and brief assessments
have been found to be cost-effective ways to reduce alcohol consumption. The AUDIT
provides a simple method of early detection of hazardous and harmful alcohol use in
primary health care settings, which makes it an appropriate measure for this study
(Appendix F). This instrument is the first of its type to be derived on the basis of a cross
national study (Saunders, Aasland, Amundsen, & Grant, 1993).
HCV Stigma Scale (modified) - The concept of HCV stigma is based on the work
o f Goffman (1963), who pioneered the concept of stigma. It suggests that situations
exist, which spoils one’s social identity. Stigma related to HCV has been found to have
negative effects on self-esteem, access to health care, employment, social support, and
effects on their overall health status and well-being (Crockett & Gifford, 2004). The
standardized measure exploring HCV-related stigma in this study will utilize the HIV
Stigma Scale (Berger, Ferrans, & Lashley, 2001); this was modified and renamed the
HCV Stigma Scale (Appendix C) by this researcher. The discrediting attributes o f which
Goffman spoke may take the form of physical deformity, blemishes of character, and
tribal stigma (1963). Any or all of these forms of stigma can impact persons living with
HCV. The Transactional Model of Stress and Coping for this descriptive correlational
study includes concepts from Medical Outcomes Study QOL Model; this provides
understanding of chronic illnesses and related factors that affect QOL.
IMPLICATIONS TO RESEARCH, EDUCATION, PRACTICE, AND POLICY
The identification of factors that influence QOL in HCV patients has the potential
to give direction to the development of nursing interventions or culturally-based care that
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may improve life quality in AI/AN HCV patients (Bushy, 2008; Randall & Muneta,
2000). This study will help to identify the level of depression, alcohol consumption,
stigma, and QOL among AI/AN HCV patients. Additionally, the study will examine
whether there is a relationship between depression, alcohol consumption, stigma, and
QOL in AI/AN HCV patients. Persons with HCV may need training in coping skills to
effectively deal with the stresses of living with hepatitis and life in general (EvansCampbell, 2008; Lillie-Blanton & Roubideaux, 2005). The results of this study may have
important implications for hepatitis education, treatment, Al health care policy, and
practice improvements (Buffington & Jones, 2007; Lowe, 2008). Information from this
study may help nurses develop interventions to facilitate effective coping strategies and
improve QOL of HCV patients.
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Chapter 2
Review o f the Literature

The purpose of this chapter is to present a review and critique of published
research and theoretical literature representative o f the current knowledge base of QOL
and persons living with HCV. The literature discussed here lends support to the
significance of exploring AI/ANs with HCV as a way to further understand the
relationships between depression, alcohol consumption, stigma, and QOL. This review
of the literature examines the body o f work and current state of the science.
The conceptual framework and underpinnings for this study is based on the
literature and concepts of depression, alcohol consumption, stigma, and QOL. There is a
dearth of research that collectively focuses on depression, alcohol consumption, stigma,
and QOL within the hepatitis literature. It is through the contextual lens of QOL that this
research can add to the science of HCV research and nursing practice. This study and its
focused areas of concepts among HCV patients will expand on this area of scholarship
with support of the current literature and science.
Concepts
QUALITY OF LIFE
In recent decades, there has been a broadened emphasis in the literature regarding
QOL measurement of health outcomes. The importance of QOL ruminates beyond the
scope of health indicators such as mortality and morbidity. This particular emphasis is
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comprised of: evaluating patient-reported functional health status’ using the Duke Health
Profile (Parkerson, 1994); describing physical, emotional, and social function using the
McMaster Health Index instrument (Chambers, 1993); or measuring indicator of health
status with the MOS SF-36 Health Survey (Ware, Kosinkski, & Gandek, 2002). There is,
however, a subjective component present within the context of defining QOL. It is those
distinctive personal experiences and circumstances that shape an individuals’ perspective
on QOL (Gallegos-Orozco et al., 2003; Hennessy, Moriarty, Zack, Scherr, & Backbill,
1994). This broadened research emphasis in QOL has produced variations in general
health status and QOL instruments. They comprise of broad concepts of well-being
indicators to a more focused, disease-specific measures anticipated to identify clinically
significant changes associated with specific settings (Younossi et al., 2001).
The increased number of persons, over four million in the U.S., living with HCV
has shifted the emphasis from a health care system focused only on curative measures
and quantity of life to enhancement of QOL (CDC, 2001; IOM, 2010b). In 2005, 133
million Americans, approximately one out of every two adults - had at least one chronic
illness (Foster, 2009; Wu & Green, 2000). Moreover, the trajectory of chronic illness
acquiesces suffering and reduces QOL (Alter, 2002; Strauss & Dias Teixeira, 2006). In
the latter part of the 20th century, the WHO broadly defined health as a state o f physical,
mental, and social well-being not merely the absence of disease and infirmity (Grad,
2002).
The World Health Organization (1997) defines the term QOL as an individual’s
perception of his/her position in life in the context of the culture and value systems in
which he/she live. And, in relation to his/her goals, expectations, standards, and
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concerns. It is a broad ranging concept affected in a complex way by the person’s
physical health, psychological state, level of independence, social relationships, personal
beliefs, and his/her relationship to significant features of his/her environment (Bailey et
al., 2009). Viktor Frankl (1963, 2004) asserts that QOL is tied to perception of meaning.
This quest for meaning is central to the human condition as we are brought in touch with
a sense of meaning when we reflect on that which we have created, loved, believed in, or
left as a legacy.
The considerable influence on utilization o f health care resources and substantial
harm to one’s well-being has necessitated further exploration o f QOL in an AI/AN HCV
population. The CDC (2000) views QOL as a broad multidimensional concept that
usually includes subjective evaluations o f both positive and negative aspects of life. The
overall concept allows for an interdisciplinary focus among various disciplines and
stakeholders to benchmark QOL as an overarching public health goal and national health
standard of measure (NIDDK, 2006). The QOL standardized measure has many uses
including: medication practice, research, audit, policy making, and in assessing the
effectiveness and importance of varying treatments. It can also be beneficial in assessing
variation in QOL across diverse populations, to compare subgroups within similar
cultural groups and to measure differences across time in response to alteration in life
circumstances (Stewart & Ware, 1992). The literature review regarding SF-12v2 and
AI/ANs yielded veiy few studies but other QOL studies focusing on AI/ANs were
identified.
A study by Johnson, Nowatzki, & Coons (1996) identified a sample population of
Pima Indians {n = 54) living with diabetes mellitus (DM). Health status questionnaires
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were administered and QOL was measured in collaboration with an outpatient pharmacy
in southern Arizona. The SF-36 Health Survey was utilized to assess QOL. Internal
consistencies o f the eight multi-item scales o f the SF-36 were estimated. Nonparametric
analyses were performed to determine relationships between mean SF-36 scale scores
and various clinical and demographic variables. Favorable internal consistencies were
observed for the multi-item scales, with the coefficient a ranging from 0.63 to 0.91. The
SF-36 scale scores were not influenced by sex or education level. Age was found to be
significantly associated among four o f the eight dimensions. Indicators of glycemic
control were not significantly associated with any SF-36 multi-item scale scores.
Subjects with more comorbid chronic conditions had significantly lower SF-36 scores.
If the goal of maximizing Al health status is to be achieved, QOL assessment should be
utilized as a means to monitor progress toward that goal.
Another population study provided evidence of poorer QOL among Al
participants with comorbid DM and hypertension (HTN). The relationship between QOL
and different types of help-seeking differed depending on the comorbidity status of the
participants. Jiang, Beals, Whitsell, Robideaux, and Manson (2009) evaluated QOL of
AIs living with DM, HTN, or both conditions using the SF-36. They also explored how
QOL is associated with help-seeking among AIs—with and without these chronic
conditions. Secondary data analysis was conducted on data obtained from Al participants
with DM and/or HTN from a larger epidemiological study of two Al tribes. The
participants with DM and HTN had the lowest QOL on all eight subscales of the SF-36.
Confirmatory factor analysis revealed the assumption of equivalent factor loadings for
participants with and without DM and/or HTN was not satisfied. The usefulness of
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traditional healers (Novins, Beals, Moore, Spicer, & Manson, 2004), a form of helpseeking, was significantly inversely related to physical factor scores for all the
respondents except those with DM only.
Dwight et al. (2000) concluded disability and fatigue were more closely related to
depression severity than to hepatic disease severity. The target population consisted of
chronic hepatitis C (CMC) patients (n = 50) being evaluated through structured interviews
using standardized measures. The objective was to examine the extent to which fatigue
and functional disability correlate with severity of depressive symptoms in persons with
HCV. Bonkovsky and Woolley (1999) also evaluated the effects of CHC infection on a
sample of patients' perceptions and whether treatment with interferon improved QOL.
The investigators concluded CHC patients with or without cirrhosis had significant
reduction in QOL. A total of 642 patients with liver disease, enrolled in an interferon
drug trial study for CHC, were evaluated for QOL using the SF-36 and other measures
derived from the MOS. Persons with CHC were compared with a healthy control group
(n = 750); the CHC group at baseline reported lower HRQOL on all eight scales o f the
SF-36 (p < .001 for all). Persons without cirrhosis (« = 284) reported similar, however,
slightly smaller reduction in QOL. Overall, successful interferon therapy provides
meaningful improvements in QOL in persons with CHC.
Fontana and colleagues (2002) used a large sample o f CHC patients (n = 220) not
receiving anti-viral therapy and the prevalence, type, and severity of emotional distress
among was examined. This study involved a Brief Symptom Inventory (BSI)
(Derogatis, 1993) and a 67-item questionnaire with an embedded SF-36 instrument
(Fontana et al., 2002). The BSI provides patient-reported data and an overview of
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patient symptoms and intensity at a specific point in time. The Global Severity Index
(GSI) is designed to help quantify severity-of-illness and provides a single composite
score for measuring the outcome of a treatment program based on reducing symptom
severity (Derogatis, 1993). This study showed clinically significant emotional distress
being reported in 35% of persons with CHC not receiving antiviral therapy. In addition
to depression (Wessely & Pariante, 2002), a wide range of psychological symptoms was
discerned that merits further inquiry into the causes and treatment o f emotional distress
in persons with CHC viral illness (Palmer, 2004).
DEPRESSION
According to the diagnostic criteria described by the Diagnostic and Statistical
Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR; American Psychiatric
Association, 2000), major depressive disorder is defined as experiencing either depressed
mood or loss of interest or pleasure. Along with at least four other symptoms that reflect
a change in functioning, such as problems with sleeping, eating, energy, concentration,
and/or self image, for a period o f two weeks or longer. Clinical depression is a serious
medical illness that is much more than temporarily feeling sad or blue. It involves the
disruptions in mood, concentration, sleep, activity level, interests, appetite, and social
behavior.
Although depression is highly treatable, it is frequently a life-long condition in
which periods of wellness alternate with recurrences of illness. One area of particular
concern is suicide (Shaffer, 1988) when depression is left untreated. According to the
IHS (2009b), AI/ANs die at higher rates than other Americans from alcoholism (517%),
tuberculosis (533%), motor vehicle crashes (203%), diabetes (210%), unintentional

injuries (150%), homicide (87%), and suicide (60%). The prevalence and manifestations
contrast depending on background differences and areas of residence (Manson, Shore, &
Bloom, 1985).
The validity of using western measures of depression has also led to a concern
with AI/AN populations due to vast differences in cultural beliefs, mental illness, cultural
labeling of different emotions, variability of depression manifestations (rarely DSM-IV
criteria), and conceptual language differences (Manson, Ackerson, Dick, Baron, &
Fleming, 1990). A study of adult AIs o f a Northwest Coast Tribe demonstrated little
differentiation between physical and emotional distress (Somervell et al., 1992). There
are many AI/AN cultural differences that exist in seeking mental health services and in
reporting distress. In addition, there is the much-researched phenomenon of historical
trauma and distrust of the outside population among many AI/AN communities (Brave
Heart, 1998; Evans-Campbell, 2008; Steinman, 2005; Weaver & Brave Heart, 1999;
Whitbeck, Adams, Hoyt, & Chen, 2004).
AI/ANs tend to have negative opinions of non-IHS providers, and the majority of
AI/ANs prefer the utilization of their own traditional healing practices (Rhoades &
Rhoades, 2000). Compared to the general population, AI/AN individuals are inclined to
underutilize mental health services, have higher therapy dropout rates, and are less likely
to respond to treatment. The term depressed and anxious or any term relevant to a
clinical psychological view are notably absent from most AI/AN languages and are not
conceptualized in the AI/AN traditional health belief system. A culturally different
expression of illness, such as ghost sickness and heartbreak syndrome, do not correspond
to conventional DSM diagnostic criteria.
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Living in a stressful environment has potentially negative mental health
consequences. Approximately 26% of AI/AN live in poverty, as compared to 13% of the
general population, and 10% of Caucasian Americans. In a Northern Plains study, 61%
of the children had experienced a traumatic event (Middlebrook, 2009). The AI/AN
population reports higher rates of frequent distress than the general population. There is
a high prevalence of substance abuse and alcohol dependence that is tied to a high risk for
concurrent mental health problems. Alcohol abuse is a problem for a substantial portion
of the AI/AN adult population, but varies widely among different tribes (National
Alliance on Mental Illness, 2003).
The Great Smoky Mountain study found the prevalence of psychiatric disorders is
similar among Al and Caucasian American youth in the same geographic area; however,
there are significantly higher rates of substance abuse in Al children (Costello, Farmer,
Angold, Bums, & Erkanli, 1997). A study of ANs in a community mental health center
found that substance abuse was the reason for 85% of men and 65% of women to seek
mental health care. A study by Middlebrook (2009) found that Northern Plains’ youth
diagnosed with any depressive disorder, 60% also had substance disorders.
The prevalence of suicide is a strong indication for the necessity of mental health
services in the AI/AN community (Bender, 2003, 2006; Borowsky, Resnick, Ireland, &
Blum, 1999; Broderick, 2009; Pettingell et al., 2008). AI/AN males have one of the
highest documented suicide rates in the world. Suicide rates are particularly high among
Al males, ages 15-24, who account for 64% of all suicides by AI/AN individuals
(Alcantara & Gone, 2007; Wissow, Walkup, Barlow, Reid, & Kane, 2001; Yoder,
Whitebeck, Hoyt, & LaFromboise, 2006). A study of Eskimo children in Nome, Alaska,
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found previous suicide attempts to be one of the most common problems for those
seeking mental health care (Aoun & Gregory, 1998; Kleinfeld & Bloom, 1977).
Mental health programs are available for the AI/AN community, but are in need
of improvement (Neligh, 1990). The IHS is a federal agency within the U.S. Department
of Health and Human Services (U.S. DHHS) that is responsible for providing health care
services to AI/ANs. There are 12 IHS Area Offices across the country; which oversee the
delivery of health care services. They provide administrative and technical support and
offer a variety of care services including mental health, alcohol and substance use
prevention (IHS, 2008,201 la). In a large national study (the Behavioral Risk Factor
Surveillance System), 3,940 AI/AN adults were surveyed in 36 states concerning
drinking patterns. Respondents were compared by age and sex to non-Hispanic White
respondents. Contrary to stereotypes, AI/AN men reported lower levels of chronic
drinking than non-Hispanic White men at older ages. AI/AN reported less current
drinking but about the same amount of binge drinking as non-Hispanic Whites by age and
sex, with all groups o f women reporting low levels of chronic drinking (Denny & Taylor,
2001).
Depression is a common and highly treatable disorder affecting over 17-20
million Americans annually. When left untreated and/or under-treated, depression is the
leading cause of suicide in the U.S. (IOM, 2002; Substance Abuse and Mental Health
Services Administration (SAMHSA), 2011). Once identified, depression can almost
always be successfully treated. Unfortunately, there is limited information available
about the prevalence of mental illness between AI/AN~more specifically women. The
two major studies conducted—The Epidemiologic Catchment Area Study and the
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National Comorbidity Survey—did not report data on AI/ANs. The prevalence among
AI/AN populations are problematic because they may be susceptible to unique factors
that may affect their vulnerability to mental illness (Brave Heart & DeBruyn, 1998).
Awareness and knowledge is the first step to prevention and successful treatment.
Available evidence suggests mental illnesses impact approximately 20 percent of
the total AI/AN population. The overall mental health picture for AI/ANs is not fully
documented; previous studies are restricted by small sample sizes, limited funding, racial
misclassification, and a focus on specific conditions (SAMHSA, 2011). In the AI/AN
population, high lifetime risk rates of substance use disorders, anxiety disorders, and low
socioeconomic conditions combine to give context to the greater risk for the development
of depression (Dickerson & Johnson, 2010).
Many minority women experience depression and stress brought on by persistent
racism, gender bias, violence, poverty, large family size, and social disadvantages. Yet,
access to culturally relevant therapy is rare; access to qualified mental health services is
poor, and the quality is poor. According to the 2001 Surgeon General’s report minority
women with access to mental health services are less likely than White women to use
them for reasons related to income and availability of health insurance, but also personal
history and culture (U.S. DHHS, 2001). Duran et al. (2005) state among minority
women, there is greater tendency to engage in other informal sources o f help, such as
prayer or support groups where women gather and talk with friends, hoping to gain what
others often gain by having individual therapy. The main cause for not seeking outside
treatment is lack of trust (Lowe, 2008).
Another reason minority women do not seek formal therapy is because of their

21

respective cultures. There are other ways of regaining a sense of peace and well-being.
Native American women and women of Alaskan descent often rely on traditional healers
(Randall & Muneta, 2000), who may work side by side with formal health providers in
tribal mental health programs. AI/AN women have access to some mental health care
services through IHS on their reservations, though finding culturally competent services
can be a challenge.
The CES-D scale (Radloff, 1977) is a 20-item self-report questionnaire developed
to measure and identify symptoms of depression or psychological distress in community
populations (Myers & Weissman, 1980; Roberts & Vernon, 1983). The composited
items were selected from previously validated scales and cover the major components of
depressive symptomatology. The general population were being defined as non
psychiatric persons over the age of 18. At the time of its development, researchers were
interested in the health correlates of depressive symptoms and in tracking changes in
severity of symptoms over time.
The scale has also been applied in many studies as a screen for the presence o f
depressive illness. Items were selected to represent the major components of depression
on the basis o f the clinical literature and factor analytic studies. It was designed to gauge
the major components of depression that includes depressed mood, feelings of guilt and
worthlessness, feelings of helplessness and worthlessness, psychomotor retardation, loss
of appetite, and sleep disturbance.
It is not a clinical diagnostic measure for a depression diagnosis because it only
assesses symptoms presenting in the past week and does not assess the complete range of
depressive symptoms. However, it can be used as an indicator of symptoms. It is also an

22

important measure for recognizing groups at-risk for depression, as well as the links
between behavior and depressive symptoms (Breslau, 1985). It has been developed in
the recognition of depressive symptoms in the general population; research supports the
utility of the CES-D scale in assessment studies, and as a screening tool.
The scoring of CES-D begins with participants answering items about the
regularity and length of depressive moods, thoughts, or feelings in the past week.
Participants are asked to rate each item using a 0 to 3-response scale; except for the four
positive questions, on how often you have fe lt this way during the past week. A 0
response means rarely or none o f the time (less than 1 day), 1 means some or a little o f
the time (1-2 days), 2 means occasionally or a moderate amount o f time (3—4 days), and 3
means most or all o f the time (5-7 days). In order to control for response bias, four items
(#4, 8,12, and 16) were worded in a positive direction.
The scores are summed to provide an overall score ranging from 0 to 60; higher
scores indicate more severe depressive symptoms. The total severity is calculated by
reverse scoring questions #4, 8,12, and 16 (the items that control for response bias) and
then summing all of the scores. A score of 16 or higher has been identified in early
studies (Weissman, Sholomskas, Pottenger, Prusoff, & Locke, 1977) and commonly
taken as indicative of depressive illness. They represent a range of depressed mood, from
average mood levels to high levels of depressed mood. If one’s mood score is high, they
are more likely to have trouble controlling other aspects o f their life. An example would
be that, a person might be at risk of abusing alcohol, tobacco, or other drugs excessively.
Therefore, their score may serve, as a reminder that they need to learn to control their
mood in other ways if one wants to be successful in living a healthier life.
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The interpretation of a CES-D score of less than 16 indicates clearly within the
average range o f scores for adults in the U.S. that depressed mood does not seem to be a
current issue. Whereas, scores ranging from 16 to 24, suggests borderline elevation of
depressed symptoms, compared to other adults. While depressed mood may be a source
of concern, and it may be worthwhile to learn methods to manage mood to prevent the
level of depression from getting worse (Lewinsohn, Mufioz, Youngren, & Zeiss, 1992;
Munoz, 1996). And, scores 24 or above would suggest a significant elevation of
depressed symptoms and compared to others, it would be essential to decrease the level
of depression.
The CES-D reliability and validity has been tested in African American, Asian
American, French, Greek, Hispanic, Japanese, and Yugoslavian populations (Naughton &
Wiklund, 1993). It has also been translated into several languages, including Chinese
(Cantonese and Mandarin), French, Greek, Japanese, and Spanish. The internal
consistency as measured by Cronbach a is high across a variety of populations (generally
around 0.85 in community samples and 0.90 in psychiatric samples) (Boyd, Weissman,
Thompson, & Myers, 1982; Husaini, Neff, Harrington, Hughes, & Stone, 1980). Splithalf reliability is also high, ranging from 0.77 to 0.92. Test-retest reliability studies
ranging over 2—8 weeks show moderate correlations (r = 0.51- 0.67), which is desirable
for a test of symptoms expected to show change over time. One study comparing African
American, Anglo-American, and Mexican American respondents showed no difference
in measures of internal consistency reliability (Roberts, 1980). The validity of CES-D in
an outpatient setting sample with depression, alcoholism, drug addiction, or
schizophrenia has been examined. The correlation coefficients (r) between CES-D scores
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and Symptom Checklist-90 (SCL-90), depression subscale scores were high, ranging
from 0.73 to 0.89. Correlations with the Hamilton Rating Scale for Depression (Ham-D)
scores were variable and ranged from 0.49 for patients with acute depression to 0.85 for
patients with schizophrenia. Correlations with the Raskin Scale were also variable,
ranging from 0.28 for patients with acute depression to 0.79 for patients with
schizophrenia (Weissman et al., 1977).
It should be noted that CES-D scores differ widely depending on one’s condition
in society. For example, although the mean score on the CES-D is 8.7 for people aged 25
to 74, women tend to score higher than men. Moreover, among individuals living alone,
the average CES-D score for men and women is 8.5 and 10.8, respectively. This is in
contrast to people living with others showed that, the average CES-D score for men and
women is 6.8 and 9.3, respectively. Interestingly, the average for women who are heads
o f households is 12.5. People with less education and lower income tend to score higher
(Sayetta, 1980). An assessment of the aging population using the CES-D evaluated
subsets of the original population including persons older than 64. The coefficient a
remained high (> 0.85) in this subgroup and test-retest correlations remained > 0.40. For
assessment of the measure in minority populations, the CES-D was evaluated for subsets
o f the original population including Blacks. The coefficient a remained high (> 0.85) in
this subgroup; test-retest correlation was < 0.40 for this group (Radloff, 1977). Group
means should only be used in reference to other groups. The internal reliability and
consistency is good for all groups tested (race, age, education). The CES-D design
strengths and weaknesses clearly show it is not intended as a clinical diagnostic tool and
that interpretations of individual scores should not be made (Radloff, 1977).
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Chapleski, Lamphere, Kaczynski, Lichtenberg, and Dwyer (1997) utilized the
Center for Epidemiological Studies Depression Scale (CES-D) in a study of 309 Great
Lakes Al elders from urban, rural, and reservation settings, with good internal
consistency (Curyto et al., 1998). This study also supported earlier findings of an
association between stressful life events, depressive symptoms, and decline in functional
health status. Depression is among the most prevalent psychopathologies within AI/AN
communities, but little is known about the validity and reliability of common assessment
measures in this population. Beals, Manson, Keane, and Dick (1991) describes the factor
structure of the CES-D scale, which was based on collected data from a sample (n = 605)
of Al college students. Comparisons o f the factor structure across gender indicated
differences were due largely to one item: crying. A 3-factor model fit the data well and
was judged the most parsimonious.
A clarified conceptual meaning of depression in individuals with HCV infection
is proposed based on a critical review o f literature. Moving beyond an exclusively
biomedical perspective, depression in HCV is explained by a cluster of factors that
incorporate physiological, psychological, and social dimensions. Symptom experience,
stigma, and uncertainty are factors that span the complex nature of depression in persons
with HCV. This broadened perspective incorporates individual and societal values and
beliefs regarding HCV and encompasses the multidimensional complexity of depression
in HCV. Hepatitis C-related depression presents an enormous challenge for nurses
because of its interference with treatment adherence and significant negative impact on
the person’s QOL (Gallegos-Orozco et al., 2003). Nursing theorists, researchers, and
clinicians may benefit from a clear conceptual understanding of the unique nature of
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depression in this growing segment of the U.S. population. This clarified conceptual
meaning needs to be examined through qualitative, quantitative, and longitudinal studies
with this population. It is hoped that future theorists, researchers, and practitioners will
contribute to the conceptual understanding, resulting in improved QOL for this special
population (Saunders & Cookman, 2005).
Although the incidence of HCV is declining, a large reservoir of patients with
CHC exists. Unless effective HCV antiviral regimens are developed, many patients with
asymptomatic HCV may develop clinical symptoms in 15 to 20 years. Mood disorders
are common in patients with HCV who are referred for psychiatric consultation. The
drug interferon and ribavirin are the primary treatment for CHC but can induce
depression and other mental and neuropsychiatric syndromes. Mood disorders associated
with HCV may respond to psychiatric intervention (Dolan, 1999; Yates & Gleason,
1998).
A veteran focused study examined the incidence of psychiatric comorbidities
among veterans {n = 120) with CHC. This study assessed depression, anxiety sensitivity,
post-traumatic stress symptoms, and alcohol consumption using standardized measures in
veterans with chronic HCV. Lehman and Cheung’s (2002) research revealed psychiatric
comorbidities to be very common among veterans with chronic HCV and correlated
poorly with diagnoses documented in the medical record. In chronic HCV veterans,
clinically significant levels of depression (44.2%), anxiety (38.1%), post-traumatic stress
disorder (20.8%), and alcohol-related problems (26.7%) were observed. Positive
correlations were found between post-traumatic symptoms and depressive symptoms,
anxiety sensitivity, and alcohol use problems (Nelligan et al., 2008). A correlation
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between depressive symptoms with anxiety was also identified. Overall, 79 (65.8%)
veterans had one or more possible contraindications to antiviral therapy: coexisting
unstable psychiatric disorders, and/or recent substance use was found in 73.4% of these
veterans. An implication for this study is a multidisciplinary approach that includes
psychological assessment using standardized measures in the evaluation of these patients
for antiviral therapy.
Another study examined CES-D scale reliability, construct, and predictive
validity in a HCV patient sample (n = 116) of 62 (53%) males and 54 (47%) females.
This longitudinal study tested the CES-D psychometric properties at three time intervals:
prior to treatment, at four weeks, and 24 weeks post treatment. Clark, Mahoney, Clark,
and Eriksen (2002) concluded that the CES-D is a reliable and valid instrument to screen
for depressive symptoms in HCV patients. The instrument is able to detect the predicted
increase in depression associated with HCV. However, an examination of the sensitivity
and specificity is needed to determine the most accurate cut-off score. The reliability
(Cronbach a) = 0.88 Pretreatment, 0.89 Week 4, and 0.90 Week 24. The construct
validity revealed four factors: negative affect, positive affect, somatic affect, and
depressed affect. With the exception for two items, felt sad and couldn't get going, all
items loaded distinctly with correlation coefficients in the range of 0.51 - 0.84. The
predictive validity testing revealed a statistically significant effect over time {p < 0.001)
in the direction predicted (pretreatment x = 13.97; post 4 weeks x = 19.54, and 24 weeks
x = 19.97) (Clark et al., 2002).
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ALCOHOL CONSUMPTION
The patterns of alcohol consumption and its consequences differ considerably
among minority groups. Although more research is needed, evidence supports
prevention and treatment efforts may be more effective when based on cultural
understanding of the ethnic / cultural contexts of drinking behaviors and their
development (Botvin, Schinke, Epstein, Diaz, & Botvin, 1995; Kumpfer, 1998). It is
important to note the uniqueness of racial/ethnic populations including AI/AN
communities, which differ markedly in cultural characteristics and drinking behavior.
Consequently, research does not support broad generalizations about specific
subpopulations, many of whom have not been studied individually (Beauvais, 1998;
Caetano, Clark, & Tam, 1998).
Data from nationwide surveys o f adults show that both current drinking (defined
as consumption of 12 or more drinks in the past year) and heavy drinking are most
prevalent among AI/ANs and Native Hawaiians and lowest among Asian American and
Pacific Islanders (AAPIs) (Kim, Coletti, Williams, & Hepler, 1995). Among all age and
ethnic groups, men are more likely to drink than are women, and to consume large
quantities in a single sitting. Heavy alcohol consumption is defined as five drinks on a
single day at least once a month for adults and five drinks in a row at least once during
the previous two weeks for adolescents (Johnston, O'Malley, & Bachman, 2001; Stinson
et al., 1998).
The medical consequences and research on alcohol's health effects on minority
groups has concentrated largely on cirrhosis, a progressive and often fatal liver disease
usually attributable to long-term heavy drinking (NIDDK, 2006). Analysis shows a
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strong correlation between death rates from liver cirrhosis, regardless o f cause, and
drinking levels nationwide (Singh & Hoyert, 2000). Consistent with this association,
deaths from chronic liver disease and cirrhosis are approximately four times more
prevalent among AI/ANs than among the general U.S. population (Beauvais, 1998).
Data from a nationwide survey highlights the social consequences o f drinking and
driving prevalence in the past year: 19% among AI/ANs, 11% for both Whites and
Hispanics, 7% for African Americans, and less than 6% for AAPIs (Stinson et al., 1998).
Alcohol-related fatal crashes are three times more prevalent among AI/ANs than among
the general population (Beauvais, 1998), constituting 1 of the 10 leading causes of death
among AI/ANs, along with alcohol-related suicide, homicide, and cirrhosis (Grossman,
Sugarman, Fox, & Moran, 1997).
The Alcohol Use Disorders Identification Test (AUDIT) is an instrument
designed to identify persons with HCV and assess their hazardous and harmful patterns
of alcohol consumption. The WHO developed the AUDIT as a simple method of
screening for excessive drinking and to assist in brief assessment. This measure was
developed and evaluated over a period of two decades, and has been found to provide an
accurate measure of risk across gender, age, and cultures (Volk, Steinbauer, Cantor, &
Holzer, 1997). It can assist in identifying excessive drinking as the cause of the
presenting illness.
It also provides a framework for intervention to help hazardous and harmful
drinkers reduce or cease alcohol consumption and, thereby, avoid the harmful
consequences of their drinking. The AUDIT also helps to identify alcohol dependence
and some specific consequences of harmful drinking. It is particularly designed for
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health care practitioners and a range of health settings, but, with suitable instructions, it
can be self-administered or applied by non-health professionals (Allen, Reinert, & Volk,
2001 ).

STIGMA
Today, it is an increasingly acknowledged global reality that those most deeply
affected by the HCV epidemic are also severely disadvantaged, whether based on race,
gender or sexual orientation, age, or social class (International Council of Nurses (ICN),
2003; WHO, 2001). In addition to the physical challenges HCV presents, this illness
carries with it a stigma that negatively impacts QOL for infected persons. The impact on
affected persons consists of psychological stress, reduced self-esteem, depression, fear of
disclosing HCV status, worsening disease state resulting in limited social support systems
and resources (Astone-Twerell, Strauss, & Munoz-Plaza, 2006; Van Brakel, 2006). The
landmark Surgeon General’s Report on Mental Health identifies stigma as a public health
concern, providing leverage for advocacy (Link & Phelan, 2006; U.S. DHHS, 1999). As
in the case of most other stigmatized health conditions such as HIV/AIDS, mental illness,
and sexually transmitted infections, fundamental structural inequalities, social prejudices,
and social exclusion explain why women, the homeless, veterans, substance users, sexual
minorities, and people of color are disproportionately impacted by HCV and the
accompanying stigma and discrimination (IOM, 2010a).
The nearly two decade of global history of the HCV epidemic reinforces the well
documented interaction of disease, stigma, and 'spoiled’ social identities (Goffman,
1963) based on race, ethnicity, sexuality. In attempting to further understand AI/ANs
living and experiencing HCV-related stigma, it is edifying to refer to the concept of
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stigma based on Goffman’s scholarly work. Stigma is a term with a multitude of
connotations and definitions. The concept of stigma first emerged within the social
science research through the seminal work o f Erving Goffman.
Goffman (1963) defined stigma as an attribute that is deeply discrediting and
reduces the bearer from a whole person to a tainted, discounted one. It is seen among
individuals’ who are newly diagnosed with HCV and often judge themselves harshly.
This diagnosis can bring on feelings or emotions of shame and uncleanliness. According
to the Oxford Dictionaiy (2011), the definition of stigma is a mark o f disgrace associated
with a particular circumstance, quality, or person. The Greek and Latin origins of
stigma also means to mark, brand, or tattoo. Merriam-Webster Dictionary (2011)
describes stigma as a mark o f shame or discredit; an identifying mark or characteristic; a
specific diagnostic sign o f a disease.
In general, individuals often first learn about HCV through negative media or
images and adopt misinformation about the modes o f HCV transmission. Because many
individuals who may inject drugs have HCV, there is often an automatic association
between HCV and injection drug use. It is due to these assumptions and
mischaracterizations towards the injection drug user that this association can lead to
stigma. Link and Phelan (2001) posit that stigma exists when a label sets the person apart
and links the person to undesirable stereotypes resulting in unfair treatment and
discrimination. Stigma related to HCV illness can have profound negative impacts on an
individual’s personal and social relationships, workplace environment, community, and
access to health care. Stigma occurs when individuals are negatively judged and/or
discredited because they have HCV.
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An exemplary research study by Buseh, Kelber, Stevens, and Park (2008)
explored the relationship of symptom prevalence and intensity, perceptions of health, and
stigma on QOL. This cross-sectional correlational descriptive study consisted of a
sample of (n = 55) HIV-infected African Americans, all urban, age ranging 23-66 years
(M = 48.84, SD = 7.67), and average length of time since HIV diagnosis 10.79 years (SD
= 6.4). The measures consisted o f 5 instruments: (a) sociodemographic characteristics,
(b) Holzemer Signs and Symptom Checklist for HIV (Holzemer, Hudson, Kirksey,
Hamilton, & Bakken, 2001), (c) a perception of health single-item question, (d) HIV
Stigma Scale (Berger, Ferrans, & Lashley, 2001), and (e) Holmes’ HIV/AIDS-Targeted
QOL Scale (Holmes & Shea, 1998).
The most prevalent symptoms were fatigue (98%), fear (92.7%), shortness of
breath (92.7%), gastrointestinal upset (85.5%), numbness (80.0%), and headache
(76.4%). Symptoms with the highest reported prevalence and greatest intensity were
gastrointestinal upset, body changes, fear, and fatigue. The intensity o f symptoms was
significantly correlated with measures of stigma (r = .320, p <.025) and QOL (r = -.425,
p <.002). This study emphasizes the importance of incorporating a holistic view o f the
relationship o f symptoms with QOL (Buseh et al., 2008).
Franke and colleagues (2010) conducted a study to validate a Spanish version and
create a valid and reliable abridged version of the Berger HIV Stigma Scale in an urban
Spanish-speaking population in Peru. The Spanish version of the full HIV Stigma Scale
was shown to be internally reliable, demonstrated good construct validity, and was
sensitive to change over time. This was an observational study in whcih HIV-infected
adult participants were enrolled in order to examine the effectiveness of a community-
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based antiretroviral therapy adherence intervention. Approximately half of participants
were female, and the median age at enrollment was 30.5 years. The full HIV Stigma
Scale was abbreviated, containing 21 of the 40 original items, and revealed properties
similar to the full Spanish version (Franke et al., 2010).
Moore, Hawley, and Bradley (2009) set out to identify and categorize stigmas
associated with HCV. This was a qualitative approach consisting of a sample (n = 39) of
participants' written narratives describing stigmatic events. These narratives were in
response to a question that incorporated a functional definition of stigma that was
completed during support group meetings. Approximately 85% experienced hepatitis Crelated stigma and these findings expanded current knowledge of the stigma
complexities. Upon qualitative data saturation, a total o f five themes and 16 concepts
emerged. Nursing practice implications consisted of a comprehensive structural and
institutional application of policy. Also, population and peer education about HCV and
potential stigma would be a worthy opponent to the problem at hand.
Interventions to reduce stigma are crucial for improving care, QOL, and
emotional health for AI/ANs living with HCV. Extant research has shown that stigma
can be lessened through an array of intervention strategies that include increasing
knowledge and community awareness about HCV, counseling treatment, acquiring new
coping skills, and/or increasing contact with infected or affected individuals (Brown,
Macintyre, & Trujillo, 2003).
CONCEPTUAL MODEL
The framework underlying this study is derived from the literature based on the
concepts of QOL, depression, alcohol consumption, and stigma (Figure 1). Living with a
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HCV diagnosis can be a significant stressor for AI/AN persons and their families, social
support system, and communities (Whitbeck, Adams, Hoyt, & Chen, 2004). The
responsibilities and burden of living with HCV and its complications can lead to
reactions such as psychological stress, denial, anger, and even depression (Johnson,
Gryczynski, & Wiechelt, 2007; Neumeister et al., 2007). Over time, these responses may
be short-lived and some patients, invariably, learn to cope with HCV and life in general.
However, there may be some who experience prolonged and lingering feelings of stress
and depression and are unable to adapt to living with HCV. A possible explanation for
the development of depressive symptoms in patients with HCV is based on the
Transactional Model of Stress and Coping, in that, persons who develop depressive
symptoms may cope with HCV differently than persons who do not develop symptoms of
depression, anger, or stress (Lazarus & Folkman, 1984).

M odel
Stigma
(Stigma Scale modified)

Quality!
of Life
S(SF-12v2)|

Demographic Variables
(Age, Gender, Marital
status, Education,
Length of tim e w/
HCV, Comorbidities,
Antiviral tX (interferon/
ribavirin)

Figure 1 Conceptual Model: QOL in AI/AN persons with HCV
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In summary, this chapter presented a review and critique of published research
and theoretical literature that is representative of the current knowledge of QOL,
depression, alcohol consumption, and stigma. The literature discussed lends support to
the importance of continuing to examine these relationships so that culturally appropriate
interventions may be developed to improve life quality in AI/AN persons living with
HCV. Through the contextual lens of QOL, this research can further add to the science
of HCV research and practice. This study and its focused areas o f concepts among HCV
patients will expand this area of scholarship with the support of current literature and
science.
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Chapter 3
Methodology

The purpose of this chapter is to describe the methodology employed in this
study, to explore the relationships among depression, alcohol consumption, stigma, and
QOL among AI/AN adults living with HCV. The theoretical perspectives and
underpinnings for this research study are based on QOL, depression, alcohol
consumption, and stigma. This study aims to advance our understanding of the
measurement of QOL among AI/AN HCV patients. This chapter will describe the
research design, population and sample, instrument procedures, data collection
approaches, data analysis strategies, and the protection of human subjects.

Specific Aims:
Aim #1:

Characterize the level o f depression, alcohol consumption, stigma,
and quality of life among a sample of AI/ANs living with HCV.

Aim #2:

Examine the relationship among the variables of age, gender, residing
on an AI/AN reservation, current partner status, marital status,
depression, alcohol consumption, and stigma with quality of life in a
sample of AI/ANs living with HCV.

Aim #3:

Identify factors that explain the greatest amount of variance in the
quality of life of AI/ANs living with HCV.
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DESIGN
A descriptive, correlational, cross-sectional survey design was used for this study.
The goal of a descriptive correlational approach is to describe the data collected and
relationships that exist among variables in a situation. Descriptive studies are aimed to
find out what is, so observational and survey methods are frequently exercised to collect
descriptive data (Borg & Gall, 1989). Descriptive studies facilitate reporting summary
data on measures of central tendency that includes the mean, median, mode, and deviance
from the mean, variation, percentage, and correlation between variables. The crosssectional survey research design often goes beyond the descriptive statistics in order to
draw inferences (Mertler & Vannatta, 2002; Vogt, 2005).
SAMPLE
A purposive sample of individuals who are receiving health care services for their
HCV disease were recruited from two health care programs serving AI/ANs in the
Southwest region of the U.S. The inclusion criteria for this study consists of: a confirmed
diagnosis of HCV with detectable HCV RNA levels at the beginning of medical
treatment; may or may not be undergoing antiviral therapy with interferon and/or
ribavirin; ability to read and comprehend English; ability to comprehend and complete
study instruments; and voluntary willingness to participate in the research study. The
exclusion criteria include: less than 18 years of age; psychiatric or medical disturbance
that impedes full participation and informed consent process; or a potential participant’s
decision to decline research study participation.
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SAMPLE SIZE
Sample size was determined by power analysis applying a small effect size o f 0.3,
level of significance (a = .05), with a statistical power = .80. The desired sample size (n
= 82) for this study was calculated using Power and Precision 4 developed by Borenstein,
Hedges, Rothstein, Cohen, & Schoenfeld (2010). Power is the probability of detecting a
particular effect size, given a specific alpha level and is determined by sample size,
measurement error, alpha level, effect size, and number o f control variables. A power of
.80 or greater is desirable (Borenstein, Rothstein, Cohen, Schoenfeld, Berlin, & Lakatos,
2000).
SETTING
The research setting for participant recruitment was at two health care programs
serving AI/ANs in the areas of Southern California and Southwest Arizona. The first site
consists of a tribal health care clinic providing a full spectrum of on-site and outreach
services and programs to their communities and other AI/ANs residing within their
catchment area. Site 2 is a facility funded directly by IHS and provides services to more
than 35,000 AI/ANs within their catchment or service area unit. The second site consists
of a hospital and provides comprehensive care ranging from primary care (inpatient &
outpatient) to tertiary care and specialty services. These site locations are considered
ideal, target communities to this investigator’s research study.
PROTOCOL/ PROCEDURES
A collaborative effort with the clinic health care providers and medical staff was
established to assist with identification and recruitment o f potential study participants and
obtain informed consent. When a potential participant had been identified, this
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investigator and/or health care staff provided an overall description and purpose o f the
research study. The participant(s) were informed about what would be gleaned from this
research study’s findings and how it has the potential for future programmatic
development and community education focusing on improved HCV services.
The primary investigator was available to answer questions. Participants were
informed that the standard of care would not be altered should they decide to not
participate in this research study. An attempt to recruit adult participants of various age
groups, equal number of gender, and a varied representation of AI/ANs who receive
health services within these study sites. Recruitment included: (1) an invitation letter for
study participation and research participant consent form; (2) an opportunity to review,
ask questions, and (3) to choose to participant by signing the informed consent.
Participants who signed informed consent were interviewed by the primary
investigator for approximately 60 minutes. This was to ensure that all survey instruments
were completed at a time and setting appropriate, convenient, and private for the
participants. A monetary incentive was provided in the form of a gift card or cash to
acknowledge the participant’s time and participation (Appendix N and O). On 12
February 2011, the principal investigator completed the NIH Office of Extramural
Research course in “Protecting Human Participants” prior to obtaining Institution Review
Board (IRB) approval. The research study packet included: an Invitation Letter for Study
Participation (Appendix H and I) explaining the research study and invitation; a Letter of
Support from the healthcare organization’s Executive Officer and/or IRB Chairperson
(community / cultural stakeholders) (Appendix A and B); a Research Participant Consent
Form and Projectal Subject’s Bill of Rights (Appendix J, K, L, M); four standardized
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instrument questionnaires (Appendix P, Q, R, S), and Personal and Clinical Data
Collection form (Appendix T and U).
DATA COLLECTION
Approval was obtained from the University o f San Diego IRB (Appendix C and
D) and two study sites (Appendix E, F and G), respectively. The primary investigator
met with eligible participants after their scheduled clinic appointments to explain the
research study and to answer questions. The participants who agreed to participate were
provided an opportunity to review and sign the research study informed consent form.
Research data were de-identified with a coded number assigned by the primary
investigator and data were securely stored.
INSTRUMENTS
Each of the key constructs in the proposed model were measured using self-report
instruments. In the following section, a description o f each of the instruments utilized to
measure QOL, depression, alcohol consumption, and stigma is provided. Instruments
were selected on the basis of their applicability for self-report, reliability and validity, and
limited response burden. Demographic characteristics and clinical factors related to HCV
are also described.
Quality of Life - Short Form-12v2 (SF-12v2) - The outcome variable, QOL will
be measured using the SF-12v2 questionnaire, which has been widely implemented in
social and psychological research. A 12-item instrument, the SF-12v2, is one of several
multipurpose health surveys that measures health status and was constructed from a
subset of 149 core items developed during the Medical Outcome Study (Stewart & Ware,
1993). The physical component subscale (PCS) is an overall measure o f physical health
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and a reflection of an individual’s satisfaction with their perceived level of physical
function, mobility and role limitations due to their health status. The mental component
subscale (MCS) is an overall measure of mental health impacted by depression, sense of
well-being, and the ability to participate in social activities.
The SF-12v2 is a 12-item subset from the SF-36v2 and has demonstrated
equivalent mean scores for the physical and mental component subscales of HRQOL
among general and disease-specific populations (Scientific Advisory Committee of the
Medical Outcomes Trust, 2002; Ware, Kosinski, Tumer-Bowker, & Gandek, 2002). This
instrument measures the same eight health domains: Physical Functioning, Role-Physical,
Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental
Health (Fleishman, Selim, & Kazis, 2010).
The SF-12v2 reproduces more than 90% of the variance of the PCS and MCS of
the SF-36 in the general U.S. population, takes significantly less time to complete than
the SF-36, reducing burden on research participants, and demonstrated high two-week
test-retest reliability correlations for both PCS (r - 0.89) and MCS (r = 0.76). Applied
extensively in HRQOL research, the SF-12v2 survey is convenient, may be completed in
less than two minutes, to monitor health changes, or analyze and compare disease burden
in the general population (Cheak-Zamora, Wyrwich, & McBride, 2009). The subscales
of the SF-12v2 have been found to be internally consistent with reported Cronbach a of
.87 (PCS) and .82 (MCS), respectively.
Center for Epidemiologic Studies-Depression (CES-D) scale - The CES-D scale
(Radloff, 1977) is a 20-item self-report questionnaire developed to measure and identify
symptoms of depression or psychological distress in community populations (Myers &
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Weissman, 1980; Roberts, Vernon, & Rhoades, 1989). The CES-D Questionnaire (vl.O),
although it may be pragmatic to identify populations at risk of developing clinical
depression or anxiety disorders, is not intended as a clinical diagnostic tool (Radloff,
1977). Since its introduction, the CES-D has been practical to assess depression risks in
several populations (e.g., adolescent, elderly, ethnic and clinical populations) for whom it
was not originally designed.
The 20-item scale measures the following six components: depressed mood,
feelings of guilt and worthlessness, feelings of helplessness and hopelessness,
psychomotor retardation, loss of appetite, and sleep disturbance (Radloff, 1977). The
participants are asked to indicate how frequently they experienced the symptom within
the past year on a scale ranging from rarely or none of the time to most or all of the time.
Each frequency level on the CES-D is assigned a numerical score ranging from 1 to 4.
The CES-D has been shown to be a reliable measure for assessing the number,
types, and duration of depressive symptoms across racial, gender, and age categories
(Knight, Williams, McGee, & Olaman, 1997; Radloff, 1977; Roberts, Vernon, &
Rhoades, 1989). A high internal consistency has been reported with Cronbach’s a
coefficients ranging from .85 to .90 across studies (Radloff, 1977). Concurrent validity
by clinical and self-report criteria, as well as substantial evidence of construct validity has
been demonstrated (Radloff, 1977). However, there is evidence that the CES-D, while a
useful measure of the level of depressive symptoms, may not be a good tool for screening
for clinical depression or major depression (Roberts, Vernon, & Rhoades, 1989).
Alcohol Use Disorders Identification Test (AUDIT) - The AUDIT is an
instrument designed to identify persons with HCV and assess their hazardous and
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harmful patterns of alcohol consumption. The WHO developed the AUDIT as a simple
method of screening for excessive drinking and to assist in brief assessment. This
measure was developed and evaluated over a period of two decades, and it has been
found to provide an accurate measure of risk across gender, age, and cultures (Voik et
al., 1997).
It can assist in identifying excessive drinking as the cause of the presenting
illness. It also provides a framework for intervention to help hazardous and harmful
drinkers reduce or cease alcohol consumption and, thereby, avoid the harmful
consequences of their drinking. The AUDIT facilitates the identification of alcohol
dependence and some specific consequences of harmful drinking. It is particularly
designed for health care practitioners and a range of health settings, but, with suitable
instructions, it can be self-administered or used by non-health professionals (Allen et al.,
2001).
To score the AUDIT, each of the questions has a set o f responses to choose from,
and each response has a score ranging from 0 to 4. The AUDIT consists of 10 items that
can be administered quickly either verbally, written, or by computer in five minutes.
Scoring: Questions 1 through 8 are scored 0, 1, 2, 3, or 4 points. Whereas, questions 9
and 10 are scored 0,2, or 4 points. A score of 8+ on the AUDIT generally indicates atrisk, harmful, or hazardous drinking (Allen, Litten, Fertig, & Babor, 1997).
In the interview format, the interviewer records the score that corresponds to the
patient’s response in the box beside each question (Bohn, Babor, & Kranzler, 1995). All
the response scores are added and a Total score is recorded. The AUDIT can detect
alcohol problems experienced in the last year. Total scores of eight or more are
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recommended as indicators of hazardous and harmful alcohol use, as well as possible
alcohol dependence. A cut-off score of 10 will provide greater specificity but at the
expense of sensitivity (Volk et al., 1997). Since the effects o f alcohol vary with average
body weight and differences in metabolism, establishing the cut off point for all women
and men over age 65 one point lower at a score of 7 will increase sensitivity for these
population groups.
Based on experience gained in a study o f treatment matching with persons who
had a wide range of alcohol problem severity, AUDIT scores were compared with
diagnostic data that reflected low, medium, and high degrees of alcohol dependence.
AUDIT scores in the range of 8 -15 represented a medium level of alcohol problems.
Whereas, scores of 16 and above represented a high level of alcohol problems (Miller,
Zweben, DiClemente, & Rychtarik, 1992). On the basis of experience gained from the
use of the AUDIT in this and other research, it is suggested that the following
interpretation be given to AUDIT scores: Scores between 8 and 15 are most appropriate
for simple advice focused on the reduction of hazardous drinking; Scores between 16
and 19 suggest brief counseling and continued monitoring; and AUDIT scores of 20 or
above clearly warrant further diagnostic evaluation for alcohol dependence (Babor, de la
Fuente, Saunders, & Grant, 1992).
HCV Stigma Scale (modified) - Stigma, was measured using a modified version
of the HIV Stigma Scale. The HCV Stigma Scale is a measure tailored for this study
from the original version, the HIV Stigma Scale. This instrument measures stigma
perceived by persons living with HIV in the U.S., and was developed based on the
literature on stigma and psychosocial aspects of having HIV. The 40 items are centered
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on the experiences, feelings, and opinions about how persons living with HIV feel and
how they are treated. The person living with HIV responds to these items using a fourpoint scale to indicate level of agreement or disagreement.
Psychometric analyses were performed and resulted in four factors emerging from
exploratory factor analysis. Those four factors consist of: Personalized stigma,
Disclosure concerns, Negative self-image, and Concern with public attitudes toward
people living with HIV. Construct validity was supported by relationships with related
constructs: self-esteem, depression, social support, and social conflict. The ranges of the
coefficient a were between .90 and .93 for the four subscales and .96 for the 40-item
instrument provided evidence of internal consistency reliability. The HIV Stigma Scale
was reliable and valid with a large, diverse sample of persons living with HIV (Berger,
Ferrans, & Lashley, 2001).
The scoring of the modified HIV Stigma Scale and subscales begins with
participants answering items about some of the social and emotional aspects of having
HCV. This first set of questions asks about some of the experiences, feelings, and
opinions about how persons with HIV feel and how they are treated. Participants are
asked to rate each item, and to circle each answer: Strongly disagree (SD), Disagree (D),
Agree (A), or Strongly Agree (SA). Items are scored as follows; SD = 1; D = 2; A = 3;
and SA = 4.
In order to control for response bias, two items (#8 and 21) have been worded in a
positive direction. If a subject selects a response in between two options (e.g.: between
SD and D), a numerical value midway between the two options would be used (e.g.: 1.5).
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After reverse scoring these two items, each scale or subscale’s score is calculated by
simply summing up the raw values of the items belonging to that scale or subscale.
Subscale designations appear in small print in the far right margin o f the
instrument; it may be desirable to cover or delete those numbers before reproducing the
instrument for administration to participants. Sixteen items belong to more than one
subscale, reflecting the intercorrelations of the factors on which the subscales are based.
The range of possible scores depends on the number of items in the scale. For the total
HIV Stigma Scale, scores can range from 40 to 160 [1 x 40 items to 4 x 40 items]. For
the personalized stigma subscale, scores can range from 18 to 72. For the disclosure
subscale, scores can range from 10 to 40. For the negative self-image subscale, scores
can range from 13 to 52. For the public attitudes subscale, scores can range from 20 to
80 (Berger et al., 2001).
Demographic variables - Demographic characteristics and related clinical
information collected included: gender, age, race, marital status, tribal affiliation, veteran
status, level of education, HCV risk factor, type of HCV treatment, duration of HCV
treatment.
DATA ANALYSIS PLAN
The Statistical Package for Social Sciences (SPSS) Version 20 was utilized for
statistical data analysis. Prior to data analysis, each variable was examined using
frequency distributions and visual representations. Once an analysis of the demographics
of the study sample was completed (Hoskins & Mariano, 2004), the overall scale and
subscale scores of the CES-D, AUDIT, HCV Stigma (modified) scales and measurement
of the QOL PCS and MCS scores were assessed in the research study sample. An
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assessment and internal reliability of the subscales was measured using Cronbach a
(McDowell, 2006). Chi-square tests for categorical, ANOVAs, t-test, and bivariate
correlations for continuous variables were used in order to measure and describe the
relationships between the variables (Creswell, 2009). A multivariate multiple regression
analysis was utilized to examine which variables explain the greatest amount of variance
in QOL. In predictive analyses based on probability theory, the independent variables
cause variation in the value of the dependent variable (Mertler & Vannatta, 2002). The
goal is to determine how accurately one can predict the value of an outcome (dependent)
variable, QOL, based on the values of the predictor (independent) variables.
A diagnosis of HCV infection is often unexpected and can be devastating. There
is a significant impact on the QOL among persons living with HCV infection. Not only
do the clinical manifestations such as fatigue diminish functioning but also living with a
chronic stigmatized illness with an uncertain future creates dilemmas around disclosure,
accessing support, and sustaining self-esteem, employment, and relationships. In this
research study, the focus is on identifying and describing the unmet health care needs and
barriers to treatment was explored through the use o f a descriptive study using a self
administered survey comprised of the standardized measures of the SF-12v2, CES-D,
AUDIT, HCV Stigma (modified), and selected demographic variables.
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Chapter 4
Results

The purpose of this study was to explore the relationship among depression,
alcohol consumption, stigma, and quality of life among AI/ANs living with HCV. In this
chapter, the sample is described, including their scores on the predictor variables of
depression, alcohol consumption, stigma, and the outcome variable of quality of life.
This chapter concludes with the findings related to the specific research aims.
SAMPLE CHARACTERISTICS
A purposive sample of 101 AI/AN participants living with HCV was recruited
from the Southwest region of the U.S. The sample characteristics, including patient
demographics and health information/history, were collected utilizing a Personal Data
Collection form designed for this study (Appendix L). Clinical data consisting of
laboratory results were collected for participants from study Site 2 (n = 65) (Appendix
M). Relevant demographic, health information/history, and clinical data of the study
sample are reported in Tables 1,2, and 3. The sample was fairly evenly distributed by
gender with slightly more males (54.5%, n = 55) than females (43.6%, n = 44); 2% self
identified as transgender or lesbian (n = 2). The mean age was 50.56 years (SD = 8.773)
ranging from 23 to 70 years of age. Marital status was approximately equally distributed
among individuals who were divorced or separated (34.7%, n = 35), single or never
married (32.7%, n = 33), married or partnered (27.7%, n = 28), with the exception of
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widows/ers who composed 5% o f the sample (n = 5). Similarly, the sample was evenly
divided among individuals who had a primary partner (49.5%, n = 50) and those who did
not (49.5%, n = 50). Out of those who reported having a primary partner, 88.2% (n = 45)
were partnered with someone of the opposite sex and 74.5% (n = 38) currently living
with their primary partner.
The major Native / Tribal languages among the participants was Kumeyaay
(Dieguefio) (13.9%, n = 14), Navajo (Din£) (12.9%, n — 13), and O’odham (14.9%, n =
15). Approximately two-thirds (65.3%, n = 66) reported not residing on Al reservation or
land. Education level was as follows: 1% (n = 1) had attended graduate or professional
school; 5% (n = 5) had obtained a Bachelor’s degree; 34.7% (n = 35) had completed
some college; 14.9% were High School graduates (n = 15); 19.8% (n = 20) had obtained
a GED, 16.8% (n = 17) had completed some high school; 3% (n = 3) had obtained an
Associate’s degree; and 5% (n = 5) had completed Elementary school. This sample also
reported their occupational status as unable to work or unemployed (32.7%, n = 33),
disabled (26.7%, n = 27), or working full-time (26.8%, n = 27), with the majority
describing their present or most recent job or occupation in the crafts, trades, factory
work, retail, or labor industry (57.4%, n = 58). Over one-third (38.6%, n = 39) reported
an annual income of all members o f participants’ household in the range of $0 - $ 10,000.
The majority of the sample had not served in the U.S. Armed Forces (91.1%, n =
92). There were only nine respondents who reported ever serving in the U.S. Armed
Forces. There was a varied response regarding how easy it was to afford or access
medical treatment for HCV. It ranged from very easy 20.8% (n = 21), to somewhat easy
37.6% {n = 38), somewhat difficult 18.8% (n = 19), and very difficult 22.8% (n = 23).
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Approximately two-thirds reported having a type of health care coverage other than
Indian Health Services. The type of health care coverage composed of either having
Medicaid (33%, n = 37) as their health care provider or having No other coverage at all
(33.9%, n - 38). A summary of Sample Characteristics is presented in Tables 1 -4.
Table 1 Sample Characteristics
N

%

Age
2 3 -4 0

13

12.9

4 1 -5 0

34

33.7

51 - 6 0

43

42.6

61 - 7 0

11

10.0

Gender
Female

44

43.6

Male

55

54.5

Other

2

2.0

33

32.7

Married / Partnered

28

27.7

Divorced / Separated

35

34.7

Widowed

5

5.0

50

49.5

50

49.5

1

1.0

6

5.9

45

44.6

38

37.6

13

12.9

Variable

Marital Status
Single / Never Married

Primary Partner (husband, wife, significant other)
Yes
No
Don’t Know / Refuse
Primary Partner’s Gender
Same Sex
Opposite Sex
Currently lives with Primary Partner
Yes
No
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Table 2 Sample Characteristics

Variable

N

%

35
66

34.5
65.3

Total

3
96
3
14
15
1
35
5
172

1.7
55.8
1.7
8.1
8.7
0.6
20.3
2.9
100%

3.0
95.0
3.0
13.9
14.9
1.0
34.7
5.0
170.3%

Total

70
100
9
179

39.1
55.9
5.0
100%

69.3
99.0
8.9
122.2%

5
17
15
20
35
3
5
1

5.0
16.8
14.9
19.8
34.7
3.0
5.0
1.0

Reside on A l Reservation / Land
Yes
No
Race / Ethnicity
Alaska Native
American Indian
Black / African American
Hispanic / Latino
Mexican / Mexican American
Native Hawaiian / Pacific Islander
White / Caucasian
Other

Language
Native / Tribal
English
Spanish

Education
Elementary
Some High School
High School graduate
GED
Some college
Associate’s degree
Bachelor’s degree
Some graduate school

% of cases
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Table 3 Sample Characteristics

N

%

Occupational Status
Full-time
Part-time
Retired
Unable to work / Unemployed
Disabled / Handicapped

27
6
8
33
27

26.8
5.9
7.9
32.7
26.7

Income (total annual household)
< 10,000
10,001-20,000
20,001 - 30,000
30,001 -40,000
40,001 - 50,000
50,001 - 100,000
> 100,001
Don’t Know / Refused

39
17
14
9
11
5
3
3

38.6
16.8
13.9
8.9
10.9
5.0
3.0
3.0

Afford/Access Medical Treatment for HCV
Very easy
Somewhat easy
Somewhat difficult
Very difficult

21
38
19
23

20.8
37.6
18.8
22.8

Job Category - present or most recent job / occupation
Professional / Administrative
Clerical / Sales
Crafts / Trades / Labor
Healthcare / Technical
Hospitality / Service Industry
Military / Government
Unemployed / Retired

9
11
58
15
3
1
4

8.9
10.9
57.4
14.9
3.0
1.0
4.0

U.S. Armed Forces
Yes
No

9
92

8.9
91.1

Variable

53

Table 4 Sample Characteristics —Native / Tribal Language

Variable
Native / Tribal Language
Algonquian
Apache
Cahuilla
Cahuilla-Cupeno
Cherokee
Chickasaw
Choctaw
Crow
Hocak
Hopi
Kumeyaay (Diegueflo)
Lakota
Luisefio
Luisefto- Cupeflo
Menominee
Miwok
Navajo (Dine)
O’odham
Ojibwe
Potawatomi
Quechan
Shoshone
Sioux
Tlingit
Washo
Yaqui
Yukian
Yup’ik

N

%

1
6
1
1
6
1
2
1
1
3
14
4
9
5
1
1
13
15
2
1
1
1
1
1
2
3
1
2

1.0
6.0
1.0
1.0
6.0
1.0
2.0
1.0
1.0
3.0
14.0
4.0
9.0
5.0
1.0
1.0
13.0
15.0
2.0
1.0
1.0
1.0
1.0
1.0
2.0
3.0
1.0
2.0

The next section of the Personal Data Collection form focuses on the sample
characteristics of health information and history. Over half of the participants, 50.9% (n
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= 58) stated that they had not received treatment for HCV. Also reported, were those
participants who received HCV injection plus oral medications (17.5%, n = 20),
traditional or ceremonial healing (13.2%, n = 15), complementary and alternative
medicine treatment (8.8%, n = 10). The primary reason for individuals to get tested for
HCV based on the percentage of cases (79.2%, n = 80) was having risk factors, even
though they were asymptomatic at the time of testing. The other significant reasons for
getting tested were due to either blood donor screening or evaluation o f elevated liver
enzymes, 61.4% (n = 62) and 24.8% (n = 25), respectively. A summary of Sample
Health Information/History and Clinical Characteristics is presented in Table 6. The
HCV signs and/or symptoms reported most often experienced were fatigue (78.3%, n =
72), dark urine (62%, n = 57), and arthralgia (56.5%, n = 52).
Slightly more than half of the participants, (53.5%, n = 54) reported knowing that
they were a contact of a person with confirmed or suspected acute or chronic HCV
infection - (14.9%, n = 15) did not know. In the six months before symptom onset
(regardless of gender / sexual preference), over half 52.5% (» = 53) and 51.5% (n = 52)
responded as to having zero male or female sex partners. The number of participants
who have ever been treated for a sexually transmitted disease or infection was 72.3% (n =
73). A summary of Frequency - Treatmentfo r Sexually Transmitted D iseases/
Infections is presented in Table 5.
Over 80% (86.1%, n = 87) reported ever using illicit or illegal drugs. Those who
had ever used or shared a needle or syringe to inject drugs intravenously not prescribed
by a health care worker was 62.4% (n = 63). Fifty-four (53.5%) had ever used or shared
equipment to inject drugs intravenously not prescribed by a health care worker.
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Approximately two-thirds of participants (32.7%, n = 33) had been diagnosed with
diabetes mellitus by a medical doctor; and o f those, 97% (« = 32) did not share their
diabetic supplies.
Table 5 Frequency - Treatment fo r Sexually Transmitted Diseases / Infections
Sexually Transm itted Disease / Infection
Bacterial Vaginosis
Chlamydia
Gonorrhea
HepB Virus
HepC Virus
Herpes, Genital
HIV / AIDS
Pelvic Inflammatory Disease
Syphilis
Trichomonas
Vaginitis
Venereal Disease
Pediculosis Pubic (crabs)

N

% of cases

4
21
25
1

5.5%
28.8%
34.2%
1.4%
43.8%
9.6%
15.1%
13.7%
4.1%
17.8%
6.8%
6.8%
1.4%

32
7
11
10
3
13
5
5
1

Seventy-nine (78.2%) participants who reported not ever having an accidental
stick or puncture with a needle or other object contaminated with blood. A majority of
participants, 99% (« = 100), responded as never undergoing or receiving long-term
kidney hemodialysis. Approximately 16% (15.8%, n = 16) had ever received blood or
blood products by transfusion before July 1992; years received range between 1973 and
1991. Those who responded as not ever having received any outpatient intravenous
infusions and/or injections were 93.1% (n = 94).
Slightly over half (54.5%, n = 55) reported not ever and 15.8% (n = 16) did not
know if they ever been in contact with a person’s blood who had hepatitis. Slightly less
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than 2/3rds (60.4%, n - 61) responded as not ever and 20.8% ( n - 21) did not know if
they ever had been exposed to someone else’s blood who had hepatitis. The number of
participants who were ever employed in a medical or dental field involving direct contact
or exposure mucosally or to non-intact skin with human blood or infected needles was
10.9% (n = 11) with frequent or infrequent exposures, 5 and 6, respectively. A large
number, 94.1% {n = 95) stated they did not ever work as a public safety or emergency
worker having direct contact or exposure mucosally or to non-intact skin with human
blood or infected needles; 96% (n = 97) responded as not ever being a resident of a long
term care facility.
In terms of treatment and law enforcement, 63.4% (n = 64) of participants
responded as not ever being a resident o f an inpatient drug treatment program. Also,
those who were not ever a resident of a halfway house were 72.3% (n = 73). The number
of participants reported ever being incarcerated was 83.2% (n = 84). The length of
incarceration categories and frequencies are: <30 days, 3 1 -1 8 0 days, 181 - 540 days,
541 - 720 days, and >721 days, 42.9% (n = 36), 16.7% (n = 14), 10.7% (n = 9), 9.5% (n
= 8), and 20.2% (n = 17), respectively. Those who have ever received a tattoo(s) or have
any part of their body pierced (other than their ear) was 78.2% (n = 79) and 22.8% (n =
23), respectively.
The following section pertains to transplant and blood risk, there were no
participants, 100% (n = 101) who had ever been diagnosed and / or treated by a medical
doctor for hemophilia. The majority, 98% (n = 99) had not ever received blood clotting
factor concentrates produced before 1987. Those participants who ever received dental
work / oral surgery or surgery (other than oral) prior to their HCV diagnosis was 76.2%
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(n = 77) and 57.4% (n = 58), respectively. There were no participants who had ever
received a solid organ transplant before July 1992.
Table 6 Sample Health Information / History and Clinical Characteristics
N

% of cases

No treatment

58

57.4%

HCV injection + oral medication

20

19.8%

Traditional or ceremonial healing

15

14.9%

Complementary and alternative treatment

10

9.9%

HCV injection only

8

7.9%

HCV oral medication only

2

2.0%

HCV surgery - organ transplant

1

1.0%

Screening - asymptomatic, risk factors

80

79.2%

Blood / organ donor screening

62

61.4%

Elevated liver enzymes

25

24.8%

Follow-up testing for previous marker of viral hepatitis

9

8.9%

Screening - symptomatic, no risk factors

8

7.9%

Symptoms of acute hepatitis

2

2.0%

Prenatal screening

2

2.0%

Variable
Treatments received - HCV

Reasons for HCV testing

The final section will report the Clinical Data collected from study Site 2. The
data collected from study Site 2 (n = 65), 64% of total study sample (n = 101) focuses on
the clinical characteristics of laboratory and diagnostic results. The data collected was
not complete due to the diagnostic tests being not done or tests not performed. There are
specific laboratory tests performed in HCV disease screening and management. A
summary of the Clinical Predictor Variable Descriptives is presented in Table 7.

HEPATITIS C
The hepatitis C antibody (anti-HCV) is the initial test in determining if HCV
infection is present. A positive finding indicates the body’s response to HCV infection
and the body is making antibodies in order to fight the infectious process. Sixty (92%)
had a confirmed true positive for anti-HCV, which indicates infection with HCV in the
past. This type of positive test result warrants additional confirmation testing to
determine whether or not the anti-HCV is a true positive.
The hepatitis C recombinant immunoblot assay (RIBA) is the confirmation test
for the hepatitis C antibody. A positive RIBA test result confirms the detection o f a true
positive anti-HCV, which suggests HCV infection in the past. More than half of the
participants from Study site 2 (n = 40) had a positive RIBA test result showing past
infection of HCV. Again, with a positive RIBA test, an HCV RNA viral load
(quantitative) would need to be performed in order to detect the presence of HCV in the
body.
The next test, HCV polymerase chain reaction (PCR), is a qualitative test utilized to
confirm whether HCV is present. A positive test result confirms there is chronic HCV
infection. More than 80% (n = 54) had HCV PCR positive results confirming chronic
HCV infection, which is a more accurate test in detecting very low HCV levels versus the
quantitative test method. In contrast, only eight participants had a negative HCV PCR
test as a result from either successful response to HCV drug therapy or spontaneous
clearing of HCV. An equivocal test results for one participant indicates there was some
reactivity but not sufficient to be considered a positive HCV PCR finding.
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Table 7 Clinical Predictor Variable Descriptives
Variable

N(%)

Anti-HCV
60 (100.0)
Positive§
RIBA
40(100.0)
Positive§
HCV PCR
Positive
54 (87.1)
8 (12.9)
Negative
HCV Genotype
Type 1A
27(67.5)
Type IB
4 (10.0)
Type 2B
5(12.5)
Type 3A
3 (7.5)
Type 4A/C/D
1 (2.5)
Total anti-HAV
Positive
28 (75.7)
Negative
8(21.6)
Equivocal
1 (2.7)
IgM anti-HAV
Negative§
55 (100.0)
HBsAG
Positive
1 (1.8)
Negative
55 (98.2)
Total anti-HBc
5 (20.8)
Positive
Negative
19(79.2)
IgM Anti-HBc
Positive
1(1-9)
Negative
53 (98.1)
Note: * = p <00\ , p -value is Pearson Chi-Square; § = No statistics are computed because
lab result is a constant.
Globally, HCV consists of six distinct genotypes and is further classified into
many subtypes. These genotypes are considered to be the genetic structure of the virus
and lay the groundwork for the standard of care and predicted response in HCV
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treatment. Genotyping is useful in disease management in terms o f medication regimen,
dosing, and duration. In the U.S., genotypes 1,2, and 3 are most common. However,
genotype 1 is most difficult to treat and accounts for 70-75% o f all HCV infections. The
data collected from study site 2 shows that 25 participant’s HCV genotyping were not
done or tests were not performed and that antiviral treatment was not indicated. Whereas,
67.5% (n = 27), 10.0% (n = 4), 12.5% (n = 5), 7.5% (n = 3), 2.5% (n = 1) tested as
genotype 1A, IB, 2B, 3A, and 4A/4C/4D, respectively.
HEPATITIS A
The hepatitis A virus (HAV) is considered to be highly contagious and the most
prevalent type of hepatitis. It is an acute inflammatory condition of the liver with the
majority of cases being acquired by ingestion of the virus, which is shed in the stool o f
infected persons, mostly fecal-oral transmission. A concern for those who are living with
HCV is this distinct class of viral illness affecting the liver. Many of the HCV risk
factors also pose risk for HAV infection, which require screening, testing, and
prevention. The vaccine for HAV is recommended to all eligible persons and especially
those with liver disease and HCV risk factors as a preventative measure according to
CDC vaccination guidelines.
The confirmation o f HAV by testing for Total anti-HAV is required to detect
presence of any antibody against HAV and also indicate infection. Total anti-HAV
appears early during the course of infection and remains detectable for lifetime. It also
provides lifelong protection against HAV infection or disease. There was an equal
distribution for those participants who tested positive for Total anti-HAV or tests not
performed, (75.7%, n = 28). A positive interpretation results in either acute HAV or past
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HAV infection. A little over 21.6% (n = 8) tested negative for total anti-HAV and 2.7%
(n = 1) resulted in a test result of equivocal. An equivocal result means that there is some
reactivity, however, not enough to be positive or negative based on laboratory reporting
criteria.
The IgM anti-HAV test is associated with active or recent infection with HAV.
The presence of IgM antibodies is usually detected in the blood as early as two-weeks
after being infected with HAV or when symptoms o f HAV are present, and last for a few
months after symptoms subside. A large proportion (n = 55) had negative IgM anti-HAV
test results, indicating no active or recent infection with HAV.
HEPATITIS B
The HBsAg, Hepatitis B surface antigen, is a marker o f current infection. The
presence of HBsAg may also indicate either acute or chronic HBV infection. In this
sample, 55 participants tested negative for HBsAg and one tested positive, indicating
current infection.
The total anti-HBc, antibody to Hepatitis B core antigen, is a nonspecific marker
of acute, chronic, or resolved HBV infection. It appears at the onset o f symptoms in
acute Hepatitis B and persists for life. While is it not a marker of vaccine-induced
immunity, it may be utilized in pre-vaccination testing to determine previous exposure to
HBV infection. There were 19 participants that tested negative and 5 tested positive for
total anti-HBc.
The IgM antibody to Hepatitis B core antigen is a test that identifies antigens,
which is a substance on the surface of a virus that causes the immune system to recognize
it and respond. An exposure to an antigen is viewed as foreign material and the body
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takes the necessary steps to neutralize the antigen by producing antibodies. Therefore, a
positive IgM anti-HBc test result indicates recent infection with HBV. The presence of
IgM anti-HBc also may indicate acute HBV infection. A large majority (n = 53) tested
negative; (n = 1) tested positive; and (n = 11) did not have an IgM anti-HBc done or test
was not performed.
Research Questions Findings
Aim #1:

What is the level of depression, alcohol consumption, stigma, and quality
of life among a sample of AI/ANs living with HCV.

The use of descriptive statistics, means, standard deviations, and range were
calculated in order to describe the levels of depression, alcohol use, stigma, and quality of
life (PCS and PCS) in a sample of AI/ANs living with HCV (Table 8).
Table 8 Descriptive Variables Statistics
M

SD

Cronbach’s a

CES-D

20.33

13.301

.920

AUDIT

14.10

10.005

.889

STIGMA

97.07

19.756

.942

Personalized

42.14

11.019

.94

Disclosure

26.21

5.328

.78

Negative Self Image

29.29

6.54

.80

Public Attitudes

49.51

11.016

.92

QOL - PCS

41.32

11.075

.868

QOL-M CS

46.56

11.774

.879

Variable

Depression (CES-D)
The reliability coefficient for CES-D in this study a = .92 is consistent with
previously reported a ’s .85 to .90 (Radloff, 1977); .87 (Hodge & Kipnis, 1996); .88
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(Clark, Mahoney, Clark & Eriksen, 2002). The overall CES-D profile for this sample had
a mean of 20.33 (SD = 13.301) and scores ranging from 0 to 50. Higher scores on the
CES-D indicate higher levels of distress. Less than half of the sample (42.6%, n = 43)
had scores greater than 21, which is indicative of possibility of major depression that may
require further evaluation and treatment. A total o f 39 (38.6%) scored less than 15,
showing no depressive symptomatology, and 19 (18.8%) scored between 15 and 21,
indicating the presence of mild to moderate depression. A summary o f Descriptive
Statistics - CES-D is presented in Table 9.
Table 9 Descriptive Statistics - CES-D
N

%

No depression (0 -14)

39

38.6

Mild to moderate depression (15-21)

19

18.8

Possibility of major depression (22 - 50)

43

42.6

CES-D scores

Alcohol Use Disorders Identification Test (AUDIT)
The AUDIT score profile of this sample consisted of a mean of 5.23 (SD = 8.082)
scores ranging from 0 to 40. Those surveyed scoring in the range of 0 - 7 (no hazardous
drinking) was 76.2% (n —77). A range of scores between 8 - 1 5 indicate advice to
reduce hazardous drinking for 13.9% ( n - 14) of participants.
In contrast, 2.0% (n = 2) scored 17, which necessitates brief counseling and
continued monitoring; 7.9% (n = 8) scored between 2 1 - 4 0 indicating need for further
diagnostic evaluation for alcohol dependence. The reliability coefficient of the AUDIT

in this study was .89 and is consistent with previous findings .86 (Barry & Fleming,
1993; Sinclair, McRee & Babor, 1992). A summary of the Descriptive Statistics -
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Patterns o f Alcohol Consumption is presented in Table 10.
Table 10 Descriptive Statistics - Patterns o f Alcohol Consumption

N

%

No hazardous drinking (0 -7)

77

76.2%

Advise to reduce hazardous drinking (8 -15)

14

13.9%

Brief counseling and continued monitoring (16 - 20)

2

2.0%

Further diagnostic evaluation for alcohol dependence (21 - 40)

8

7.9%

AUDIT scores

HCV STIGMA
The overall total stigma score for this sample consisted of a mean of 97.07 (SD =
19.756) scores ranging from 54 to 145. The personalized subscale scores ranged from 18
to 70 with a mean of 42.14 (SD = 11.019). The level of stigma was evenly distributed for
both levels of stigma categories. The minimal to low stigma scores ranged from 18 to 40
(46.5%, n = 47) and moderate to high stigma scores range from 41 to 64 (48.5%, n = 49).
The personalized stigma addressed the perceptions or consequences o f other people
knowing that the participant is living with HCV, losing friendships, feeling that others are
displaying avoidant behavior, or having regret in divulging to some people.
The reliability coefficient of Stigma in this study is .942 which is consistent with
previous findings .96 (Berger, Ferrans & Lashley, 2001). The reliability coefficients for
each of the subscales ranged from .79 to .92 in this study compared to the reliability
coefficients for each of the subscales as reported by Berger, Ferrans & Lashley (2001)
which range from .90 to .93. A summary of Stigma Subscale scores by Levels o f Stigma
is presented in Table 11.
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Table 11 Stigma Subscale scores by Levels o f Stigma
HCV Stigma

Sample
Scores

Minimal to Low Stigma Moderate to High Stigma
(16 - 40)
(41 - 64)

Personalized

18-70

46.5%, n = 47

Disclosure

13-38

97%, 77 = 98

Negative self-image

16-47

91.1%,

= 92

8.9%,

77

=9

Public attitudes

23-76

19.8%, 77 = 20

71.3%,

77

= 72

77

48.5%, 77 = 49
77

=0

The disclosure subscale scores ranged from 13 to 38 with a mean of 26.21 (SD =
5.328). The level of disclosure stigma by category for minimal to low stigma largely
consisted of scores ranging from 17 to 38 (97%, n = 98). A majority perceived this level
of stigma by having control of their personal health status or information, keeping their
HCV status a secret, or worry that others who know of their HCV status would tell
others.
The negative self-image subscale scores ranged from 16 to 47 with a mean of
29.29 (SD = 6.540). Slightly more than 90% experienced a minimal to low level of
perceived stigma relative to negative self-image which dealt with feeling unclean, not as
good as others, or like a bad person because of HCV. The level of negative self-image
stigma by category for minimal to low stigma consisted o f scores ranging between 16 to
39 (91.1%, n - 92), and moderate to high stigma with scores ranging between 41 to 47
(8.9%, n = 9).
The public attitudes subscale scores ranged from 23 to 76 with a mean of 49.51
(SD = 11.016). The level of public attitudes stigma by category for minimal to low
stigma consisted of scores ranging between 23 to 40 (19.8%, n = 20), and moderate to
high stigma with scores ranging between 41 to 64 (71.3%, n = 72). This revealed a
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moderate to high level of perceived stigma regarding the public’s attitudes and what most
people think about a person with HCV or what most people with HCV can expect when
others learn they have HCV. A summary o f the Descriptive Statistics - HCV Stigma is
presented in Table 12.
Table 12 Descriptive Statistics - HCV Stigma

Sample
Scores

Range
Scores

M

SD

54 - 145

40-160

97.07

19.756

Personalized subscale

18-70

18-72

42.14

11.019

Disclosure subscale

13-38

10-40

26.21

5.328

Negative self-image subscale

16-47

13-52

29.29

6.54

Public attitudes subscale

23-76

20-80

49.51

11.016

HCV Stigma
Total Stigma Score

Quality of Life (SF-12v2)
The outcome variable, QOL was measured using the SF-12v2 questionnaire, a 12item instrument consisting of two subscales: physical component subscale (PCS) and
mental component subscale (MCS). The PCS is an overall measure of physical health
and a reflection of a person’s satisfaction with their perceived level of physical function,
mobility and role limitations due to their health status. In contrast, the MCS is an overall
measure of mental health impacted by depression, sense o f well-being, and the ability to
participate in social activities. The reliability coefficients for each of the subscales
ranged from .868 (PCS) and .879 (MCS) in this study compared to the reliability
coefficients for PCS and MCS as reported by Ware et al. (2002) which ranged from .89
and .86, respectively.
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The overall range of sample scores for PCS is 20 - 63 with a mean o f 41.32 (SD =
11.075). Almost 3/4* (71.3%, n = 72) reported participant’s physical health being worse
than the typical U.S. person. Less than a third 28.7% ( n - 29) reported participant’s
physical health better than the typical U.S. person. The range of scores for MCS is 21 —
71 with a mean of 46.56 (SD = 11.774). Over half, 58.4% (n = 59) reported participant’s
mental health is worse than the typical U.S. person; 41.6% (n = 42) reported mental
health better than the typical U.S. person. A summary of Descriptive Statistics - Quality
o f Life (SF-12v2) is presented in Table 13.
Table 13 Descriptive Statistics - Quality o f Life (SF-12v2)

Quality of Life (SF-I2v2)

N

%

Physical health better than typical US person

29

28.7

Physical health worse than typical US person

72

71.3

Mental health better than typical US person

42

41.6

Mental health worse than typical US person

59

58.4

Aim #2:

What is the relationship among the variables o f age, gender, residing on an
AI/AN reservation, current partner status, depression, alcohol
consumption, stigma, and quality of life (PCS, MCS) in a sample of
AI/ANs living with HCV.

Chi-square tests for categorical variables, ANOVA or t-test for continuous
variables by categorical variables, and correlations between continuous variables were
used to examine bivariate relationships between participant characteristics and quality of
life (PCS and MCS).
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Participant QOL - PCS
One-way ANOVA indicated a statistically significant relationship between PCS
and gender (F = 4.8, p = .03), and trending toward significance is the relationship
between PCS and residence on AI reservation/land (F= 3.46, p = .06). Correlational
analysis indicated a statistically significant inverse relationship between PCS and CES-D
score (r = -.438, p = .000); trending toward significance is the inverse relationship
between PCS and Stigma (r = -.183, p = .06). A summary o f the Correlation Matrix Predictor Variables and QOL is presented in Table 12.
Participant QOL - MCS
Correlational analysis indicated a statistically significant positive relationship
between MCS and Age (r = .205, p = .04); statistically significant inverse relationship
between MCS and CES-D score (r = -. 726, p - .000) and MCS and Stigma (r - -.279, p
= .005). Statistically significant inverse relationships were found between Age and CESD (r = -.220, p = .027); Age and Stigma (r = -.212, p = .034); Age and AUDIT (r = .243, p = .01); and trending toward significance for having a current primary partner (r =
.172,p = .08).
Residence on AI reservation/land was statistically significant inversely related
with AUDIT (r = -.225, p = .02) and approaching significance for having a current
primary partner (r = .189,/? = .06). A statistically significant positive relationship was
found between CES-D and AUDIT (r = .400, p = .000); CES-D and Stigma (r = .485, p
= . 000); AUDIT and Stigma approached a statistically significant positive relationship (r
= .192, p = .05). A summary of the Correlation Matrix - Predictor Variables and QOL
- PCS & MCS is presented in Table 14.
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Table 14 Correlation Matrix - Predictor Variables and QOL - PCS & MCS

1

2

1 QOL - PCS

1.000

2 Gender

.217* 1.000

3 Age (in years)

-.078 -.074

3

4

.184

.081

.090

1.000

5 QOL - MCS

.165

.144

.205*

.081

6 Current Primary Partner

.012 .000

.172

.189

8 AUDIT

I

00

9 STIGMA

-.438** -.158 -.220*
-.124

6

7

8

9

1.000

4 Resides on AI Reservation

7 CES-D

5

.100 1.000

-.130 -.726** -.088

.046 -.243* -.225*
-.175 -.212*

1.000

1.000

-.148 -.027 .400** 1.000

-.075 -.279** -.023 .485** .192* 1.000

* Correlation significant at 0.05 (2-tailed)
** Correlation significant at 0.01 (2-tailed)

Aim #3:

Identify factors that explain the greatest amount of variance in the quality
of life in a sample of AI/ANs living with HCV.

Simultaneous multiple regression analyses were conducted to examine the amount
of variance in the DV. A multiple regression approach is appropriate whenever a
quantitative variable is to be examined in relationship to predictor variables (Cohen,
Cohen, West & Aiken, 2003). This standard multiple regression strategy was suitable
because all independent variables are viewed as having equal importance, there were no
apriori hypotheses, and regression diagnostic procedures did not detect problems with
multicollinearity among the predictor variables.
Collinearity

Collinearity describes a situation when a high correlation is detected between two
or more predictor variables. When high correlations are detected, they can pose problems
when attempting to draw inferences about the relative contribution of each predictor
variable to the success of the model. In the use of simultaneous multiple regression
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method, the researcher specifies the set of predictor variables that comprises the model
(Mertler & Vannatta, 2013).
When testing for assumptions, the predictors are not highly correlated. This is
supported by Pearson correlations not being > 0.9, Variance Inflation Factor (VIF) <10,
and tolerance > 0.2. A formal method for determining the presence of multicollinearity is
the VIF. The VIF measures how much variance of estimated regression coefficients are
inflated when compared to having uncorrelated predictors (Hair, Black, Babin, &
Anderson, 2010). Tolerance was used as an indicator of multicollinearity and estimated
and calculated by regressing the predictor variables onto the remaining variables included
in the multiple regression analysis. There were no outliers and the outcome was normally
distributed. Tolerance statistics exceed 0.1 for all variables indicating multicollinearity is
not evident. A summary of collinearity statistics - PCS and MCS is presented in Table
15 and 17, respectively.
Quality o f Life
Participant QOL - PCS
Regression results indicate the overall model significantly predicts participants’ quality of
life: Participant Quality of Life - Physical Health, R2= .252, R2adj~ .195, F (7,92) =
4.429,p = .000. This model accounts for 25% of the variance in QOL-PCS. A summary
of the regression coefficients indicated only one (CES-D) of the seven variables
significantly contributed to the model (Table 16).
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Table 15 Summary o f Collinearity Statistics- PCS

Collinearity Statistics
Tolerance

VIF

Gender

.941

1.063

Age (in years)

.880

1.137

Reside on AI Reservation/Land

.909

1.100

Current Primary Partner

.932

1.073

CES-D

.651

1.535

AUDIT

.753

1.328

STIGMA

.748

1.337

Table 16 Coefficients fo r Model Variables - PCS
B

t

P

2.00

.097

1.045

.299

Age (in years)

-.208

-.166

-1.727

.087

Reside on AI Reservation/Land

3.252

.141

1.495

.138

Current Primary Partner

-.579

-.026

-.283

.778

CES-D

-.396

-.480

-4.297

.000

AUDIT

.054

.040

.380

.705

STIGMA

.017

.030

.285

.776

Independent Variables
Gender

Multiple R = .502
R2 = .252

B

R2 adj = . 195
F (7,92) = 4.42, p = .000

Participant QOL - MCS
Regression results indicate the overall model significantly predicts participants’
quality of life: Participant Quality o f Life - Mental Health, R2 = .569, R2^ - .536, F (7,
92) = 17.352,/? = .000. This model accounts for 56% o f the variance in QOL-MCS. A
summary of the regression coefficients in Table 16 indicated two (CES-D and AUDIT) of
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the seven variables significantly contributed to the model. A summary of the Coefficients
for Model Variables - MCS is presented in Table 18.
Table 17 Summary o f Collinearity Statistics- MCS

Collinearity Statistics
Tolerance

VIF

Gender

.941

1.063

Age (in years)

.880

1.137

Reside on AI Reservation/Land

.909

1.100

Current Primary Partner

.932

1.073

CES-D

.651

1.535

AUDIT

.753

1.328

STIGMA

.748

1.337

Table 18 Coefficients for Model Variables -M C S

Independent Variables

B

0

*

P

1.148

.052

.736

.463

Age (in years)

.122

.091

1.242

.217

Reside on AI Reservation/Land

.160

.006

.090

.928

Current Primary Partner

.413

.018

.248

.805

CES-D

-.729

-.824

-9.714

.000

AUDIT

.257

.177

2.239

.028

STIGMA

.067

.113

1.424

.158

Gender

Multiple R = .754
R2 adj = .536
R2 = .569
F (7, 92)= 17.35,/? = .000
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Chapter 5
Discussion and Conclusion

This chapter will provide a brief summary of the research study, relate the
findings to prior research, and suggest possible directions for future studies. This
descriptive correlational study was conducted to examine factors associated with quality
of life among AI/AN adults living with HCV. This chapter concludes with the findings
related to specific research aims that may have important implications for hepatitis
education, treatment, AI/AN health policy, and practice improvements.
HCV is a silent epidemic that is taking a toll on Indian Country and; generating
considerable concern and raising important public health challenges including long-term
health, financial, and social consequences. Quality of life, and not just health, has
emerged as an important issue for AI/ANs living with HCV. However, research on
quality of life in AI/ANs with HCV remains limited and is virtually nonexistent.
Information from this study may help nurses develop interventions that facilitate effective
coping strategies and help to advance the science to improve QOL among AI/ANs living
with HCV.
In the study reported here, depression scores indicated that 38.6% had no
depressive symptomatology; 18.8% reported the presence o f mild to moderate
depression, and 42.6%, had scores suggesting possibility of major depression. An
analysis by gender indicated a difference in depressive symptomatology where half of all
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women in this sample (n = 22) had a score indicating the possibility of having major
depression. Given the dearth of inquiry on depression and AI/ANs living with HCV,
these findings are congruent in many ways with the overall AI/AN women specific
mental health challenges and opportunities (Duran et al, 2004).
Not surprisingly, the changes HCV brings can lead many with the condition to
feel anxious, irritable, and even depressed. Among AI/AN people, there is a wide range
o f beliefs about illness, healing, and health. For the AI/AN population, the overall
concept of mental illness and beliefs as to why and how it develops contain many diverse
meanings and interpretations. Frequently there is an experiential disconnect between
physical illness and psychological distress (Hodge, Limb, & Cross, 2009). They are
often not adequately distinguished and AI/ANs may express emotional distress in ways
not consistent with standard diagnostic categories. This could explain the range of
responses overall and between gender regarding depression as measured by the CES-D.
There is a growing body of evidence suggesting that persons with HCV have a
higher prevalence of mental health illness, and persons with mental health illness have
four to nine times the prevalence of HCV (Rifai & Rosenstein, 2005, U.S. DHHS, 1999
& 2001). Depression is common, and therefore, it is important to find support through
support groups, trusted friends and family, or online communities. Interacting with
others living with HCV, persons can learn about the challenges other people are facing,
find strength and impart coping strategies with each another. The pervasiveness of
stigma that’s associated with seeking mental health care keeps AI/ANs from seeking and
ultimately receiving the necessary treatment.
It is essential for nursing and other health care providers to recognize the

75

seriousness of co-occurring depression in persons infected with HCV. Overall, the CESD provides a reliable and valid measure to screen for depressive symptoms in this
population. However, discourse bringing increased attention and focus on depression
within AI/AN communities is imperative to provide effective care and HCV disease
management.
The level of alcohol consumption measured by the AUDIT indicated for this
sample there was no association or implication o f harmful or hazardous drinking. An
analysis between gender and AUDIT showed non- significant relationship. The
relationship between residing on an AI reservation / land and pattern of alcohol
consumption was significant which is concerning in conjunction with prior findings o f
depression significantly more common among alcoholics than non-alcoholics
(Numgerger, Foroud, Flury, Meyer & Wiegand, 2002; Norton, Redd & Bryan, 2002).
There is empirical evidence for co-morbidity of mood and anxiety disorders
among AI/AN women with any lifetime substance use disorders. In this sample these co
morbidity rates among AI/AN women were higher than rates in non-AI/AN women
reported in other studies (Duran et al, 2004). The level of consumption warrants further
analysis in relation to HCV to determine safe levels of alcohol consumption, given there
was a large group of respondents scoring below the cut-off score o f not having harmful or
hazardous drinking pattern of alcohol.
Stigma produces many challenges for AI/ANs living with HCV and their social
networks, communities, and place in society. Despite the development and support by
legislation, policy, and guidelines to protect and serve persons living with HCV, evidence
continues to report stigma within their communities and even health care delivery
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systems. There was moderate to high level of personalized stigma reported as
consequences of family or community discovering they are living with HCV, losing
friendships, sensing others displaying avoidant behavior, or expressing regret in
divulging their HCV status to others. Due to the size o f some AI/AN reservations, social
networks and kinships tend to magnify their place in those communities. Notably, there
are few health care delivery systems and thus it is commonplace to exchange and share
local/tribal community news. This close knit community of AI/ANs creates apprehension
for disclosure, which could lead to friends and family discovering their HCV status and
negatively impact their social support.
A moderate to high level of stigma regarding public attitudes also dealt with
issues surrounding what most people think about a person with HCV or what most people
with HCV can expect when others learn they have HCV. The attitudes of health care
providers were thought to have been detrimental for those seeking medical treatment or
access of health care services, this has the potential to cause damaging effects, isolation,
depression, and increased disease burden and coping with their HCV status (Zickmund,
Ho, Masuda, Ippolito, & LaBrecque, 2003). The majority of participants noted living
with HCV lead to being stigmatized because of the whole association o f HCV with
injecting drug use or engagement with high-risk behavior. This misinformation leads to
assumptions that all persons living with HCV have a history of injection drug use in spite
of the many ways HCV can be acquired (Butt, 2008). In many ways, much like society
in general, AI/AN communities also lack compassion and understanding about the
injective drug using population.
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A minimal to low level of stigma related to disclosure centered around having
control of one’s personal health status or information, keeping their HCV status
confidential, or being concerned that others who knew o f their HCV status would
disclose to others. Some participants resolved to avoid disclosing their HCV status to
prevent any sort of discrimination or added stigma even from certain health or social
services worker, family, and friends. Disclosure was also seen by many to result in being
judged or condemned by their own family members, tribal community, and healthcare
setting. A segment of stigma that was not explored in this study and merits further
examination is how disclosure affects access to housing, employment, and access public
resources.
A minimal to low level of stigma related to negative self-image concentrate on
factors like feeling unclean, not as good as others, or like a bad person due of their HCV
status. Beyond the physical symptoms of HCV, the condition can take its toll on the
mental or feeling aspects of life quality. There were shared emotional responses where
participants often expressed feelings of shame and stigma from when they first heard
their diagnoses of HCV and after years of living with their illness, to today. Often,
participants conveyed their reluctance in revealing their diagnosis with others, which
further lead to feelings of isolation and loneliness.
The area of research in the concept of stigma has been overlooked within AI/AN
populations. And, more specifically within the context of living with HCV. The overall
relationship between HCV and stigma requires further study and deconstruction in order
to gain an appreciation and fully understand the current state of stigma within an
indigenous worldview. This allows for positive systematic changes in the provision of
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AI/AN healthcare, policy, and practice that can serve as a guide and provide quality care
to AI/ANs living with HCV, bringing increased HCV knowledge and awareness to
AI/AN communities, their leaders, and stakeholders.
The results are consistent when comparing participants with the general
population norm; more than half of the study sample scored below general population
norms on both the PCS, MCS, and all eight health domain subscales (Younossi, 2001).
This is an indication that the participants have worse physical and mental health than the
typical U.S. person. Alarmingly, when taking into account gender differences, there was
a significantly larger percent of female scores below the general population norm than
males for both PCS and MCS.
Again many of these factors need to be further explored to draw inferences on
specific health domains that impact quality o f life. It can be postulated that many of the
barriers demographically could be factors that impact quality of life. Many of the
potential demographics may include: type of health care coverage, HCV treatment
disparities, HCV symptoms, Education level, Income, Access to care, and HCV risk
factors, to name a few. However, other factors not included in this study could explain
quality of life and include cognitive fimction and co-morbidities, (Cordoba et al, 2003,
Hussain et al, 2001).
Correlation and simultaneous multiple regression analyses were conducted to
determine how well age, gender, residing on AI reservation / land, marital status, current
partner, depression, alcohol consumption, and stigma predicted quality of life. For the
QOL-PCS outcome, the simultaneous multiple regression model with seven predictors
produced R2= .252, indicating these predictors account for approximately 25% of the
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variability in QOL-PCS. Depression was the only independent variable to contribute to
the model. In contrast for the QOL-MCS outcome, the simultaneous multiple regression
model with all seven predictors produced R = .569, indicating these predictors account
for approximately 57.0% of the variability in QOL-MCS.

The regression analysis

indicated the model significantly predicts QOL-MCS.
Limitations of the Study
The results of the analyses must be viewed in the context o f their limitations. Due
to the small/unique sample available for the study, results may not be generalizable
beyond the specific population from which the sample was drawn. Data was collected
via a survey comprised of four measures: Personal Data, QOL, CES-D, AUDIT, and
STIGMA. It is possible that some questions were not culturally equivalent for AI/ANs
populations.
All measures was administered by the PI, thus participants could be influenced by
social desirability and human memory during self-report, which can consequently
influence data accurateness. Respondent burden could be a limitation to the data
accurateness, the length of the survey may have influenced responses, for instance several
participants appeared to be anxious about time even though the PI provided the
opportunity to complete the questionnaire before, during or after their appointment, or at
a later time of the convenience.
In addition, cross-sectional data allows for analysis at one point in time and
longitudinal data are needed both to describe the course of QOL and determine the
impact of depressive symptoms plus the co-occurring conditions on the health of the
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participants. Nonetheless, these findings are important because typically studies still do
not examine the co-occurrence of psychosocial issues particularly in AI/AN with HCV.
This study was the first to tailor the STIGMA scale for use with AI/AN with HCV
and, it demonstrated acceptable content validity, further testing of the STIGMA scale is
needed to ensure reliability and validity among HCV populations.
Implications and Recommendations
Nursing Practice Implications
HCV is a silent disease and considered a public health threat. Through robust
research and advancing the science is critical in order to improve and develop care
models targeting HCV, AI/ANs populations are underrepresented in national studies
(Lead, 2012). The American Association for the Study of Liver Diseases (AALSD) also
argue what is necessary to effectively manage liver disease is advancing clinical
guidelines as new treatment options are on the horizon and constantly evolving. There is
a mandate to remain vigilant in prevention thus advocacy is a key strategies.
The current study was completed using a descriptive cross-sectional survey
design. Additional research is needed and could be implemented using a longitudinal
design to determine if changes over time become perceptible. Further investigation can
use qualitative methods to build the theoretical foundation based on AI worldview and
mixed methods to guide practice through research.
Nurses, as advocates and change agents, can facilitate the improvement in QOL,
reducing the burden of disease, and closing the gaps in healthcare inequality. In terms of
the issues of depression, investments can be made in providing evaluation of activities
already in use among other health care models to establish practice-based evidence rather

81

than expecting evidence-based practices not developed or tested in AI/AN communities
to work effectively.
The discourse among health care disciples about screening and prevention on
alcohol use and improving HCV treatment services for eligible participants that have low
risk or abstinence from alcohol use is needed. A key strategy is to decrease stigma and
bring increased awareness and structural, systematic changes with the involvement o f key
community advisory stakeholders to educate their tribal community, health delivery
system, and government. Stigma has an impact. Through education and dialogue,
increased knowledge will reduce and eliminate the burden o f stigma.
The advent of new treatment strategies aims to achieve higher efficacy with
shorter duration, easier administration, and client adherence. The role for nurses is: to
provide continued HCV medication management and support during treatment, to ensure
adherence, and include interdisciplinary team members. HCV medication side effects are
common; patients and family members need support and encouragement throughout
treatment as it affects their quality of life. Given the wide range and potential seriousness
of adverse reactions, clients need close and regular monitoring from nurses at regular
intervals. Adherence and support during treatment is undoubtedly one of the key factors
for success in achieving a sustained viral response, which is an outcome that is a state o f
being cured.
Nursing Education Implications
The role of nursing is essential in helping patients, families, and communities
become active participants in healthcare. While the traditional methods of nursing
education for patients has fallen short in terms of targeting chronic disease and yield
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positive behavior change, the use of motivational interviewing has been shown to an
effective method in facilitation, adoption, and implementation to improve treatment
outcomes for patients and their support systems (Bishop and Jackson, 2013). An element
of cultural competence must also be an emphasis as there are many variations of AI/AN
culture that is dynamic, shared, symbolic, learned, and integrated (Dunn, 2002). This
transformational educational approach will align nursing educators and healthcare
systems initiative as exemplary accountable care organizations (ACOs).
An expansion on cultural competence would be to explore another area that may
impact health outcomes. Nurses can involve lay community health workers (CHWs) to
provide education, support, and outreach based on the needs through community-based
interdisciplinary intervention (Tyler, Nyamathi, Stein, Koniak-Griffin, Hodge, &
Gelberg, 2013). The utilization of CHWs in tribal communities are frontline public
health workers and considered by elders and lay community as trusted members and have
a close understanding of their community.
This relationship and collaboration with nursing enables CHWs to serve as
intermediaries between health care organizations and AI/AN communities to facilitate
access to services and improve quality and cultural competence health care service
delivery. To further strengthen communities, nursing educators can engage AI/AN
community advisory boards (CAB) to effectively target those areas o f need and develop
partnerships focusing on HCV Awareness, Prevention, Testing, Risk reduction, and HCV
Treatment and Support (American Academy o f Nursing, 2013). This innovative
approach will allow nurses to evaluate innovative health care models and, in turn, can
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bring it back to CABs and provide cultural competent educational models of
sustainability and community participatory research (Wame, 2006).
Depression, alcohol consumption, and stigma are all serious problems related on
some level to the QOL of AI/ANs living with HCV. Nurses have a responsibility to meet
the need of this population, however, this study, like previous studies indicate that HCV
knowledge is poor among some health care professionals. It is imperative for the QOL of
AI/ANs living with HCV that nurses continue to explore this ‘silent killer’ using both
qualitative and quantitative methods. It is through research and evidence that is culturally
based with interventions grounded on AI/AN worldviews that is critical in educating
others about effective treatment.
Nursing Policy Implications
The nation’s recent healthcare climate change of improving access to care and the
U.S. government’s commitment in providing preventive care and services is paramount
and timely. This is considered to be the most significant and far reaching health care
reform since the establishment of Medicaid and Medicare. The overarching goal of the
Patient Protection and Affordable Care Act (ACA) has the potential to benefit those
living with HCV by improving access to needed health care services and treatment; and
diagnosing viral hepatitis earlier and preventing new HCV infections.
The AC A mirrors many local government’s HCV Strategic goals to improve
access to care and treatment, strengthen community health centers, end discrimination
against pre-existing conditions (stigma), and prioritize reduction o f health disparities.
While the expansion o f healthcare coverage is currently underway, barriers still exist, as
some states have yet to agree on expanding Medicaid services to their eligible citizens.
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Also, those who are undocumented citizens will not be covered by the ACA. Other
challenges include: legal immigrants will continue to be ineligible for Medicaid for the
first 5 years in the U.S.; may not be affordable for some citizens; and requires continued
funding from Congress. The continued realization of ACA will require innovative
nursing and healthcare leadership and visionary providers, advocates, government, and
stakeholders the ensure ACA sustainability through partnerships.
Nursing Research Implications
A future consideration is to include qualitative study emphasizing illness
experience of AI/AN persons living with HCV. This would provide an AI/AN
perspective and worldview into the psychosocial consequences of living with HCV. It
would also be vital to examine illness narratives and find relationships from depression
and stigma results. This would impart another level of valuable information needed to
gain a better understanding in how persons explain the burden of depression or stigma,
successful coping, and the unique features associated with living with depression, stigma,
and HCV infection.
The need for future studies is evident. Further examination of depression, alcohol
consumption, stigma, and quality of life in different communities of AI/ANs living with
HCV is needed. Notably, larger and longitudinal studies are needed to determine
potential cause and effect relationships among depression, alcohol consumption, stigma,
and quality of life prior to designing and testing interventions aimed at increasing health
and quality of life in this population. In adequately addressing the health concerns
identified through this study, further research and expansion of other AI/AN HCV
population groups needs to focus on: data quality and accuracy to address under-
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representation of AI/ANs in population health data, the lack o f access to health care
services for AI/ANs in both rural and urban settings, lack of incorporation of traditional
health care practices, the efficacy of health promotion and disease prevention activities,
and the lack of health insurance coverage among AI/ANs.
The limitations of the mental health care system along with the systematic and
cultural barriers to care that impede health care services utilization and access for
AI/ANs. There is an urgent call for future research to address gaps in public health
knowledge about mental health care among AI/ANs, especially research focused on
pathways and barriers to care, financial infrastructure for AI/AN mental health and
testing interventions. Future research for depression may include and focus on:
interventions to build community support for mental health care; theoretical models for
contextualizing care within communities and systems of care; and development o f brief
interventions embedded in community settings, or delivered by telephone. Overall,
additional research is necessary to elucidate the complexities of HCV infection that
impact AI/AN populations.
Conclusion
The purpose of this study was to examine the relationship between depression,
alcohol consumption, stigma, and quality of life in the AI/AN populations. A review of
the literature reveals a need for additional research to examine the how AI/ANs are living
with HCV and compare the effects of their HCV status, stigma, alcohol consumption, and
depression on QOL dimensions. Findings indicate depression is significantly related to
QOL, with stigma approaching significance for AI/AN with HCV infection.
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The information regarding HCV infection in the U.S. is improving but there are
still many opportunities for improvement and narrowing the gaps in our knowledge.
These developments are necessary to enable better prevention, screening, testing,
treatment, disease management of HCV, and to guide research, planning for those with
hepatitis C disease. The government, health care delivery systems, and stakeholders have
put in place, underpinned by the Affordable Care Act, a comprehensive response to
address the health care issues for the uninsured and underinsured.
The advent of new therapies, innovative research, infrastructure, and health policy
there are yet many challenges and opportunities in raising the health status o f those
persons living with HCV. The paradigm of care aligns itself very much with the
philosophy of nursing. Through the continued efforts of nursing scholarship and
leadership and recent introduction of unified national health structure for our health
services, the opportunity to develop a collective nursing approach to this disease should
not be overlooked.
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Indian H e a l t h Council^ Inc.
March 28,2012
Clinic 6* Main
O ffic e

Re: Quality o f Life among Hepatitis C American Indians in Rural
Southern California

SOIOOGolsh Road
Valley C enter, CA
92082
Mali: P.O. Box 406
Paurru Valley, CA
92061
(760) 749 1410
Fax (760) 749-1S64

S a n ta Y sabel
S atellite Clinic
P.O. Box 10
Santa Ysabel, CA
92070

Dear Mr. Todicheeney,
Your project referenced above w as reviewed and approved in
accordance with the Indian Health Council, Inc. (IHC) IRB assurance
and federal requirements pertaining to human subjects protections
within the Code of Federal Regulations (45 CFR 46; 21 CFR 50). In
addition, your brochure and flyer for the project were also approved.
This review is valid through March 28, 2013, and applies to the
conditions and procedures described in your protocol. Please notify the
IHC IRB Committee if your status a s an USD student changes while
conducting this research.

(760) 765-1220

www.indianheaHh.com

Your study recruitment will take place through IHC, but you must
confirm those procedures with IHC staff prior to initiation of your study.
If study recruitment takes place outside of IHC, you must confirm with
that institution that you have permission to conduct the study prior to
initiation of any study activities.
Your Consent Form must display the USD IRB stamp of approval along
with the IHC IRB stamp of approval and must be read aloud to
participants.
This approval, based on the degree of risk, is for 365 days from the
date of IHC IRB review and approval unless otherwise stated in this
letter. The regulations require that continuing review be conducted on
or before the 1-year anniversary date of the IHC IRB approval, even
thought the research activity may not begin until som e time after the
IRB has given approval.
Date of IRB review and approval: March 28,2012
If you have any questions, please contact me: dmorton@ ucsd.edu.

Deborah J. Morton, PhD, MA, Chair
Indian Health Council, Inc., Institutional Review Board
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DEPARTMENT O F HEALTH & HUMAN SER V IC ES

Public Health Service

Phoenix Area Indian Health Service
Two Renaissance Square
40 North Central, Suite 600
Phoenix, Arizona 85004-4424
December 7, 2012

Rydell Todicheeney, MSN, MBA/HCM
Doctoral Candidate
Hahn School of Nursing and Health Science
University of San Diego
5998 Alcala Park
San Diego, CA 92110

Dear Mr. Todicheeney,
Thank you for submitting the protocol ““Quality of Life among Southwest American Indian/Alaska
Natives Living with Hepatitis C In Urban Dwellings.' It has been assigned the protocol number PXR
12.18. Please utilize this designation in any documentation and in all communication to the Phoenix Area
IHS IRB related to this study.
Upon review by the Phoenix Area IHS IRB your protocol was ‘Approved with recommendations.” Work
may begin once the IRB receives a response of needed information. The Phoenix IHS IRB had the
following recommendations that require a response:
Specific to the questionnaire to be used, the reviewers would like a response to the following:
* Are validated questionnaires being used?
o QOL and HCV stigma scale - provide clarification on their statistical reliability/validity
o PI stated the HCV stigma scale was an ‘adapted* instrument. If it was revised from another
scale, what or how was it adjusted to ‘fit’ the study? - making an adjustment to an
established instrument requires some effort and documentation related to reliability and
validity - how was the validity of the ‘adapted* instrument demonstrated?
Upon receipt of the response to the recommendations by the Phoenix Area IRB, the research may begin.
Your study is approved tor one year, through December 2, 2013.
Please be aware that any substantive changes in research activities may not be initiated without prior
review and approval by the Phoenix Area IHS IRB. Federal regulation requires that any unanticipated
problems involving risks to participants or others, or serious harm involving participants, be promptly
reported to the IRB tor immediate review. If findings for this research are to be used in any papers tor
publication, abstracts, oral or other presentations, this must be submitted to the Phoenix Area IHS IRB
before such activity is undertaken.
Please submit a Status Report and Renewal Application 30 days prior to the expiration date of this
approval, November 2, 2013. The Status Report and Renewal Application form, along with additional
information is available at www.ihs.oov/MedicalProorams/Research/index.cfm Go to Human Subject
Protection IRB then Forms and Other Resources.
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DEPARTMENT O F HEALTH & HUMAN SER V IC ES

Public Health Service

Phoenix Area Indian Health Service
Two Renaissance Square
40 North Central, Suite 600
Phoenix, Arizona 85004-4424
January 28, 2013

Rydell Todicheeney, MSN, MBA/HCM
Doctoral Candidate
Hahn School of Nursing and Health Science
University of San Diego
5998 Alcala Park
San Diego, CA 92110

Dear Mr. Todicheeney,
Thank you lor submitting a response, per the IRB's request, for protocol PXR 12.18 -“Quality of Ufa
among Southwest American Indian/Alaska Natives Living with Hepatitis C in Urban Dwellings '
Upon review by the Phoenix Area IHS IRB, your protocol was approved *as is’, and your research can
begin. Your study is approved for one year, through December 2,2013.
Please be aware that any substantive changes in research activities may not be initiated without prior
review and approval by the Phoenix Area IHS IRB. Federal regulation requires that any unanticipated
problems involving risks to participants or others, or serious harm involving participants, be promptly
reported to the IRB for immediate review. If findings for this research are to be used in any papers for
publication, abstracts, oral or other presentations, this must be submitted to the Phoenix Area IHS IRB
before such activity is undertaken.
Please submit a Status Report and Renewal Application 30 days prior to the expiration date of this
approval, November 2, 2013. The Status Report and Renewal Application form, along with additional
information is available at www.ihs.oov/MedicalProarams/Research/index.cfm Go to Human Subject
Protection IRB then Forms and Other Resources.
On behalf of the IRB, thank you, and we wish you success with your research. If I may be of further
assistance please contact me.
Sincerely,

Cynthia Claus, PhD, MPH
Chair, Phoenix Area Institutional Review Board
Director, Office of Health Programs
Phoenix Area Indian Health Service
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In v itatio n L e tte r fo r S tu d y P a rtic ip atio n

19 March 2012
Dear Patient of Indian Health Council, Inc.:
This Invitation Letter for Study Participation has received support from
Indian Health Council, Inc. on behalf of Dale Todicheeney, a Navajo nurse
who served our community and is a University of San Diego doctoral
student. You are being invited to participate in a research study that Dale is
conducting for the purpose of learning more about patients living with the
Hepatitis C Virus.
For participating in this study, you will receive $25 Cash or a $25
Target Gift card. While Dr. Calac and his staff have mailed this letter to
IHC patients who might be interested in a study like this, Dr. Calac or
IHC is not sponsoring or funding this study. Nothing about your care at
IHC or anything about your medical care/social services will change if you
decide not to participate.
Your participation in this study about Hepatitis C is important and
completely voluntary. If you are interested in participating, you will
spend at least 60 minutes to complete the survey interview. You will have
an opportunity to sit down with Dale at a private location, most likely at
IHC, that is convenient for you and feel your privacy will be protected.
I hope you will be interested in participating and should you have any
questions, please call Dale Todicheeney at 602-315-1315 or email him at
dtodicheeney@gmail.com. Thank you.
Respectfully yours,
Dale Todicheeney, PhD(c), MBA/HCM, RN, PHN, ACNS-BC
Doctoral Student
Hahn School of Nursing and Health Science
University of San Diego
KF.F.P TH IS FOR YOI R RECORDS
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Invitation L e tte r fo r S tu d y P a rtic ip a tio n

14 August 2012
Dear P1MC Patient:
This Invitation Letter for Study Participation has received support from
Phoenix Area IHS on behalf of Dale Todicheeney, a Navajo nurse in our
community and University of San Diego doctoral student. You are being
invited to participate in a research study that Dale is conducting for the
purpose of learning more about patients living with the Hepatitis C Virus.
For participating in this study, you will receive $25 Cash or a $25
Target Gift card. While PIMC has provided you this letter and have
expressed interest in participating in this study, PIMC is not sponsoring
or funding this study. Nothing about your care at PIMC or anything
about your medical care/social services will change if you decide not to
participate.
Your participation in this study about Hepatitis C is important and
completely voluntary. If you are interested in participating, you will
spend at least 60 minutes with Dale to complete the survey interview. You
will have an opportunity to sit down with Dale at a private location, most
likely at PIMC, that is convenient and feel your privacy will be protected.
I hope you will be interested in participating and should you have any
questions, please call Dale Todicheeney at 602-315-1315 or email him at
dtodicheeney@gmail.com. Thank you.
Respectfully yours,
Dale Todicheeney, PhD(c), MSN, MBA/HCM, RN, PHN, ACNS-BC
Doctoral Student
Hahn School of Nursing and Health Science
University of San Diego
KF.EP THIS FOR \ O l R R l ( ORDS
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ID Code # _____________

Today’s D ate:__________/ 2012/2013
University o f San Diego
Institutional Review Board
Research Participant C onsent
For

Form

the research study entitled:

Quality o f Life Among Hepatitis C American Indian/Alaska N atives in Rural Southern California
I. Purpose of the research study

Dale Todicheeney. a student from the University of San Diego (USD) is conducting a study to find out
more about Hepatitis C virus (HCV) among American Indian/Alaska Natives (AI/ANs). You have been
invited because you are: living with HCV, AI/AN,utilizing Indian Health Council, Inc. (IHC) services.
II. What you will be asked to do

If you agree to be in this study, personal health information pertaining to your HCV diagnosis will be
included in this study. This study involves questionnaires to better understand how you are living with
HCV. The interview will last 60 minutes.
III. Foreseeable risks or discom forts

You will not be identified with your responses. No one but Dale will know how you answered these
questions. Dale is responsible for managing the data and certified in confidentiality procedures.
Som etim es when people are asked to think about their feelin gs, they may feel sa d or anxious. If
you would like to talk to so m eon e about your feelin g s at any time, you may call:
Indian Health Council, Inc. - Human S ervices Department at 760-749-1410 or
San Diego Mental Health Hotline at 1-800-479-3339
IV. Benefits and risks

Participation may involve a slight risk of loss of confidentiality, as none of the data gathered is highly
sensitive. There may be no direct benefit to you; however, an indirect benefit is to know you are
helping your community and health professionals to better understand how AI/ANs are living with HCV.
V. Confidentiality

Any information provided will remain confidential and be locked in a file and/or password-protected
computer for a minimum of five years. All data collected will be coded with a number and your real
name will not be used. The results of this study will only be presentedinaggregate form.
VI. Compensation
You will receive a $25 Target Gift card or $25 Cash for participating, even if you do not com plete
the se ssio n .
VII. Voluntary Nature of this Research
Your participation Is entirely voluntary. You may refuse to answer any question or withdraw at any

time. Deciding not to participate or not answering any of the questions will have no effect on any
benefits you’re entitled to, like your health care, or employment. You can withdraw from this study at
any time without penalty.
VIII. Contact Information

Dale has explained this study to me and answered my questions. The participant will be told if any
important new information is found during the course of this study that may affect willingness to
continue. You may contact Dale at (602) 315-1316 or the USD Institutional Review Board at (619) 2604653 for more information about your rights as a participant, or to report research-related problems.
Agreement: I have read and understand th is form, and co n se n t to the research it d escrib es to
me. I have received a copy of this co n sen t form for my records.

Print Name I Signature of Participant

Dale

Rydell ‘Dale’ Todicheeney. PhDfci. RN I___________________________________________________
Signature of Study Inveetigator
Date
KF.F.P T IIIS FOR Y O l R RF C ORDS
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Institutional Review Board
Indian Health Council, Inc.
50100 Golsh Road
Valley Center, CA 92082
(7 60) 749-1410
(7 6 0 ) 749-1564 (FAX)
PROJECTAL SUBJECTS BILL OF RIGHTS

The faculty and staff of the University of San Diego and Indian Health Council, Inc. wish you to know:
Any person who is requested to consent to participate as a subject in a research study involving a
medical project, or who is requested to consent on behalf of another, has the right to:
1. Be informed of the nature and purpose of the project.
2. Be given an explanation of the procedure to be followed in a research project, and any drug or
device to be used.
3. Be given a description of any attendant discomforts and risks reasonably to be expected from
the project.
4. Be given an explanation of any benefits to the participant reasonably to be expected from the
project, if applicable.
5. Be given a disclosure of any appropriate alternative procedures, drugs, or devices that might be
advantageous to the participant, and their relative risks and benefits.
6. Be informed of the avenues of medical treatment, if any, available to the participant after the
project if complications should arise.
7. Be given an opportunity to ask any questions concerning the project or the procedures
involved.
8. Be instructed that consent to participate in the research project may be withdrawn at any time,
and the participant may discontinue participation in the research project without prejudice.
9. Be given a copy of a signed and dated written consent form when one is required.
10. Be given the opportunity to decide to consent or not to consent to a project without the
intervention of any element of force, fraud, deceit, duress, coercion, or undue influence on the
participant's decision.
If you have questions regarding the research project. Dale Todicheeney, PhD(c), RN or the Research
Study's Interview Supervisor, Cynthia D. Connelly, PhD, RN, FAAN will be glad to answer them. You
may seek information from the Indian Health Council, Inc. Institutional Review Board - established for
the protection of volunteers in research projects - by calling or by writing to the above address.
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*
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Based o n th e resu lts o f th is research p roject, w e m a y co n d u ct fu tu re stu d ie s. T here Is no
obligation to participate in a fu tu re stu d y if you p articip ate in th e p r e se n t stu d y.
P lea se indicate h o w ev er, if you a g ree fo r u s to c o n ta c t you in th e fu tu re a b o u t p o ssib le
participation in an y future stu d ies.

May we contact you in the future about additional research?

□ Yes

Q No

If you checked yes, please provide your contact information (address, email, telephone):

KEEP T HIS FO R V O l R RECORDS
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ID Code # _____________

Today’s Date: _________2013
University of San Diego
Institutional Review Board
R esearch Participant C onsent Form

For the research study entitled:
Quality of Life am ong S ou th w est American indian/Alaska Natives
Living with Hepatitis C In Urban Dwellings
i. Purpose of the research study

Dale Todicheeney, a student from the University of San Diego (USD) is conducting a study to find out
more about Hepatitis C virus (HCV) among Southwest American Indian/Alaska Natives (AI/ANs). You
have been invited because you are: living with HCV, AI/AN, and utilizing Phoenix Indian Medical Center
(PIMC) healthcare services.
li. What vou will be asked to do

If you agree to be in this study, personal health information pertaining to your HCV diagnosis will be
included in this study. This study involves questionnaires to better understand how you are living with
HCV. The interview will last 60 minutes.
III. Foreseeable risks or discom forts

You will not be identified with your responses. No one but Dale will know how you answered these
questions. Dale is responsible for managing the data and certified in confidentiality procedures.
Som etim es when people are ask ed to think about their feelin g s, they may feel sa d or anxious. If
you would like to talk to so m eo n e about your feelin g s at any time, you may call:
Arizona Crisis Hotline at 1*866-205-5229
IV. Benefits and risks

Participation may involve a slight risk of loss of confidentiality, as none of the data gathered is highly
sensitive. There may be no direct benefit to you; however, an indirect benefit is to know you are
helping your community and health professionals to better understand how AI/ANs are living with HCV.
V. Confidentiality

Any information provided will remain confidential and be locked in a file and/or password-protected
computer for a minimum of five years. All data collected will be coded with a number and your real
name will not be used. The results of this study will only be presented in aggregate form.
VI. Compensation
You will receive a $25 Target Gift card or $25 Cash for participating, even if you do not com plete
the se ssio n .
Vli. Voluntary Nature o f this Research
Your participation is entirely voluntary. You may refuse to answer any question or withdraw at any

time. Nothing about your care at PIMC or anything about your medical care/social services will change
if you decide not to participate or answer any of the questions. You can withdraw from this study at
any time without penalty.
Vli I. Contact Information

Dale has explained this study to me and answered my questions. The participant will be told if any
important new information is found during the course of this study that may affect willingness to
continue. You may contact Dale at (602) 315-1315 or the USD Institutional Review Board at (619) 2604553 for more information about your rights as a participant, or to report research-related problems.
Agreement: I have read and understand this form, and co n se n t to the research it d escrib es to
me. I have received a copy of this co n sen t form for my records.

Print Name I Signature of Participant

Data

Rydell ■Date* Todicheeney. PtiDtcL RN I___________________________________________________
Signature of Study Investigator
Date
KFf'.P TH IS FOR > O i R R K O R D S
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PROJECTAL SUBJECT'S BILL OF RIGHTS

The faculty and staff of the University of San Diego and Phoenix Area IHS / PIMC wish you to know:
Any person who is requested to consent to participate as a subject in a research study involving a
medical project, or who is requested to consent on behalf of another, has the right to:
1. Be informed of the nature and purpose of the project,
2. Be given an explanation of the procedure to be followed in a research project, and any drug or
device to be used,
3. Be given a description of any attendant discomforts and risks reasonably to be expected from
the project,
4. Be given an explanation of any benefits to the participant reasonably to be expected from the
project, if applicable,
5. Be given a disclosure of any appropriate alternative procedures, drugs, or devices that might be
advantageous to the participant, and their relative risks and benefits,
6. Be informed of the avenues of medical treatment, if any, available to the participant after the
project, if complications should arise,
7. Be given an opportunity to ask any questions concerning the project or the procedures
involved,
8. Be instructed that consent to participate in the research project may be withdrawn at any time,
and the participant may discontinue participation in the research project without prejudice,
9. Be given a copy of a signed and dated written consent form when one is required, and
10. Be given the opportunity to decide to consent or not to consent to a project without the
intervention of any element of force, fraud, deceit, duress, coercion, or undue influence on the
participant's decision.
If you have questions regarding the research project, Dale Todicheeney, PhD(c), RN or the Research
Study's Interview Supervisor, Cynthia D. Connelly, PhD, RN, FAAN will be glad to answer them. You
may seek information from the Phoenix Area IHS - Institutional Review Board - established for the
protection of volunteers in research projects - by calling (602) 364-5189 or writing to: Two
Renaissance Square, 40 North Central Avenue, Suite 600, Phoenix, Arizona 85004.
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

B ased o n th e resu lts o f th is research project, w e m ay c o n d u ct fu tu re stu d ie s. T here is no
ob ligation to participate in a fu tu re stu d y if y ou p articip ate in th e p r e se n t stu d y .
P lea se Indicate h o w ev er, if you a g r e e fo r u s t o c o n ta c t yo u in th e fu tu re a b o u t p o ssib le
participation in an y future stu d ie s.

May we contact you in the future about additional research?

□ Yes

0 No

If you checked yes, please provide your contact information (address, e-mail, telephone):
Address:

_____________________

E-mail:
Telephone:
KEEP TH IS FOR V O l R RECORDS
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Institutional Review Board
Indian Health Council, Inc.
50100 Golsh Road
Valley Center, CA 92082
(7 60) 749-1410
(7 60) 749-1564 (FAX)
HCV Research Study Participant Incentive

For your voluntary participation in this HCV Research Study, you may choose one
o f the following incentives. Please check the box indicating which incentive you
would like to receive:

$25 Target Gift card

CB200030000
82
—

C6200030000

BF 0U 2 5 3 6 7 9
F6
_

k
i

B F 0U 2S3679A

Print Name / Signature of Participant

Date

Rvdell ‘Pale* Todichecnav. PhPicl. RN /___________________________________________________
Signature of Study Investigator
Date
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2013

Today's Date:.

ID Code #
University o f San D iego
Institutional Review Board

Research Participant Incentive Form

For your voluntary participation in this HCV Research Study, you may choose one
of the following incentives. Please check the box indicating which incentive you
would like to receive:

%

I | $25 Target Gift card

CB20003000D
82
—

8F0U 253679 A
F6
_
i

\ tub r a n w wmm

\

QTAMKHftG*.

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

Print Name / Signature of Participant

Date

Rvdell ‘Dale’ Todicheeney. PhDtci. RN /___________________________________________________
Signature of Study Investigator
Date
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Appendix Q

Today’s Date:__________ _

CES-D Scale Questionnaire
Instructions: This questionnaire contains 20 statem en ts people might m ake about how they feel.
P le a se d o n o t write y o u r n a m e o n th is form . P lease read each statem ent carefully and pick
the best response that best indicates how o ften y o u fe lt th a t w a y during th e p a s t w eek . For
e a c h item , circle you r an sw er: Then circle the num ber below the response you have picked.
Raniy or
none of Hie

genie ere
MUeofthe

Oeeaaienadyera
moderate amount

ahneotattof

|<1 day)

(M days)

(S4deys)

(S-7 days)

1. I was bothered by things that usually don’t bother me

0

2

3

2. I did not feel like eating; appetite was poor

0

2

3

0

2

3

2

3

2

3

2

3

8 . 1fen hopeful about the future

0
0
0
0
0

9. I thought my life had been a failure
10. I fen fearful

3. I felt that I could not shake off the blues, even with help
from my family or friends
4. I felt that I was just as good as other people
5. I had trouble keeping my mind on what I was doing
6. I felt depressed
7 . 1felt that everything I did was an effort

2

3

2

3

0

2

3

0

2

3

11. My sleep was restless

0

2

3

12. I was happy

0

2

3

1 3 .1talked less than usual

0

2

3

14. I felt lonely

0

2

3

15. People were unfriendly

0

2

3

16. I enjoyed life

0

2

3

17. I had crying spells

0

2

3

18. Ifensad

0

2

3

19. I fMt that people disliked me

0

3

20. I could not get going

0

2
2

Thank you fo r taking the tim e to
com plete the CES-D S cale Q uestionnaire!
i
Center for Epidemiological Studies Depression Scale Questionnaire (CES-D)

3
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Appendix R

ID Code #

_______________________

Today’s Date:_

Alcohol Use Disorders Identification Test (AUDIT)
Script: Now I'm going to ask 10 questions about Alcohol Use and have made a 'response card'
with answer choices to help you select the best response
Instructions: Alcohol use can affect o n e ’s health and interfere with certain medications &
treatments. It’s important that I ask som e questions about alcohol use. Please do your best
to answer each question honestly. To help you answer correctly, I have listed the standard drink
serving size on the next page. For each o f the following q u estion s, p lea se mark a ■ In the box that
b — t d w c rib n

vour answer. Please do not write vour name on this form
Nm t

1 How often do you have a drink containing alcohol?
S k i p t o Q u e s ti o n a 9 a n d 10 I t a n s e r e r fo r 9 1 a N E V E R

□

.

1 or 2

2 How many standard drinks containing alcohol do
you have on a typical day when drinking?

□

.

Monthly
o f lees

□

M im a
monSi

.

□ a

3 or 4

S o rS

□

,

□

a

a s Swim
aw e
□

□ r

a

7,S ,o rS
□

4 or ir o n

IS or m a n

□ r

a

U M th M
Nwr

3 How often do you have six or more drinks on one
Occasi0n?s*ip to Q u e s ti o n * 9 4 10 I f T o ta l S c o r e fo r i 2*3*0
4 During the past year, how often have you found
that you were not able to stop drinking once you
had started?
5 During the past year, how often have you failed to
do what was normally expected of you because of
drinking?
6 During the past year, how often have you needed
a drink in the morning to get yourself going after a
heavy drinking session?
7 During the past year, how often have you had a
feeling of guilt or remorse after drinking?
8 During the past year, have you been unable to
remember what happened the night before
because you had been drinking?

9 Have you or someone else been Injured as a
result of your drinking?
10 Has a relative or friend, doctor or other health
worker been concerned about your drinking or

□

M o n a*

DoByor
•Snoot
doSy

Wookly

.

□

a

□

a

□ o

□ .

□ .

□

a

□

a

C L

□ .

□ ,

□

a

□

a

□ a

□ .

□ ,

□

a

□ ,

□ a

□

.

□

,

□ a

□ a

□

a

□ .

□

,

□ a

□ a

□

a

.

□

NO

Yoo, but not
SiSw poM
«oor

□ .

□ a

□ ,

Q 2

Ym, during

thepast
fs a r

□

i

su g g ested you cut down?

Total S co re:_____________
Please, stop here!

This con clu d es th is sectio n . Thank you for taking th e tim e to a n sw er th e Alcohol
U se survey!
Adapted from The Alcohol Use Disorders identification Test (AUDIT), GuifeHnes for Use in Primary Care by the World Health Organization.
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Today’s D ate:_________

Alcohol Use Disorders Identification Test (AUDIT)
Rating your score
0 - 7:
8-15:

You're at low risk for problems caused by drinking alcohol.
You could be at risk for problems caused by drinking alcohol.
Making changes in your drinking habits can help lower your risk.
Above 16: Scores above 16 could mean drinking alcohol is causing problems
in your life.
Talk to your health care provider about these questions and your
score. He or she will be able to work with you to help you cut down or
stop drinking, and discuss any concerns or questions you may have.

Standard serving o f one drink:

■

T

j

12 ounces of beer or wine cooler
1.5 ounces of 80 proof liquor
5 ounces of wine
4 ounces of brandy, liqueur or aperitif

Thank you,
for taking the time to complete
the AUDIT Screening Tool!
2
Adapted from The Alcohol Use Disorders identification Test (AUDIT), Guidelines for Use in Primary C are by the World Health Organization.
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Today’s D ate:___________

HCV Stigma Scale - (modified)
Instructions: This survey asks about some o f the social and emotional aspects o f having HCV. Please do
your best to answer each question. Some questions may look like others, but each one is different. If you
are unsure about how to answer a question, please give the best answer you can. For most o f the questions,
just circle the letters that go with your answer. There are no right or wrong answers.
Feel free to write in comments as you go through the questions. Please do not write your name on this
form. This first set o f questions asks about some o f your experiences, feelings, and opinions as to how
people with HCV feel and how they are treated. For each item, circle your answer: Strongly Disagree
(SD), Disagree (D), Agree (A), or Strongly Agree (SA).
I 'M *
M M gm

<*>
D

(A>

■ M *
A «m
<*A>

1. In many areas o f my life, no one knows that I have HCV.................................

<**)
SD

A

SA

2 . 1 feel guilty because I have HCV..........................................................................

SD

D

A

SA

3. People's attitudes about HCV make me feel worse about myself.....................

SD

D

A

SA

4. Telling someone I have HCV is risky.................................................................

SD

D

A

SA

5. People with HCV lose their jobs when their employers find out......................

SD

D

A

SA

6 . 1 work hard to keep my HCV a secret.................................................................

SD

D

A

SA

7 . 1 feel I am not as good a person as others because I have HCV........................

SD

D

A

SA

8 .1 never feel ashamed o f having HCV..................................................................

SD

D

A

SA

9. People with HCV are treated like outcasts..........................................................

SD

D

A

SA

10. Most people believe that a person who has HCV is dirty................................

SD

D

A

SA

11. It is easier to avoid new friendships than worry about telling someone that I
have HCV............................................................................................................
12. Having HCV makes me feel unclean................................................................

SD

D

A

SA

SD

D

A

SA

13. Since learning I have HCV, I feel set apart and isolated from the rest o f the

SD

D

A

SA

14. Most people think that a person with HCV is disgusting.............................

SD

D

A

SA

15. Having HCV makes me feel that I'm a bad person..........................................

SD

D

A

SA

Please, continue to next page
1
C Barbara Berger 1996 (Berger's HIV Stigma Scale modified with permission)
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Today’s Date:

HCV Stigma Scale - (modified)
For each item, circle your answer: Strongly disagree (SD), Disagree (D), Agree (A), or Strongly Agree
(SA).
*»-«r
IlM g M
<SA>
(A)
<»>
SA
16. Most people with HCV are rejected when others find out............................
SD
D
A
17.1 am very careful who I tell that I have HCV.................................................

SD

D

A

SA

18. Some people who know I have HCV have grown more distant...................

SD

D

A

SA

19. Since learning I have HCV, 1 worry about people discriminating against me

SD

D

A

SA

20. Most people are uncomfortable around someone with HCV........................

SD

D

A

SA

21.1 never feel the need to hide the fact that I have HCV.................................

SD

D

A

SA

2 2 .1 worry that people may judge me when they learn I have HCV.................

SD

D

A

SA

23. Having HCV in my body is disgusting to m e................................................

SD

D

A

SA

Instructions: Manv of the items in this next section assume that vou have told other people that vou have
HCV, or that others know. This may not be true for you. If the item refers to something that has not
actually happened to you, please imagine yourself in that situation.
For each item, circle your answer: Strongly Disagree (SD), Disagree (D), Agree (A), or Strongly
Agree (SA) based on how you think you would feel or how you think others would react to you.
S tn a U r
Dfaagn*
(80)

M ugm
(B)

A gm
(A)

am a*;
A |n t
<*A)

2 4 .1 have been hurt by how people reacted to learning I have HCV.................

SD

D

A

SA

2 5 .1 worry that people who know I have HCV will tell others..........................

SD

D

A

SA

2 6 .1 regret having told some people that I have HCV........................................

SD

D

A

SA

27. As a rule, telling others that I have HCV has been a mistake.......................

SD

D

A

SA

28. Some people avoid touching me once they know I have HCV.....................

SD

D

A

SA

29. People I care about stopped calling after learning I have HCV

SD

D

A

SA

Please, continue to next page
2
© B aitara Berger 1996 (Berger's HIV Stigma Scale modified with permission)
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Today’s Date:

HCV Stigma Scale - (modified)
For each item, circle your answer: Strongly Disagree (SD), Disagree (D), Agree (A), or Strongly
Agree (SA) based on how you think you would feel or how you think others would react to you.
SMartr
»»«■*
**«
urn
(A)
<m
30. People have told me that getting HCV is what I deserve for how I lived my
life
31. Some people close to me are afraid others will reject them if it becomes
known that I have HCV
32. People don't want me around their children once they know I have HCV

SD

D

A

SA

SD

D

A

SA

SD

D

A

SA

33. People have physically backed away from me when they learn I have HCV

SD

D

A

SA

34. Some people act as though it's my fault I have HCV

SD

D

A

SA

3 5 .1 have stopped socializing with some people because o f their reactions to
my having HCV
3 6 .1 have lost friends by telling them I have HCV

SD

D

A

SA

SD

D

A

SA

3 7 .1 have told people close to me to keep the fact that I have HCV a secret

SD

D

A

SA

38. People who know I have HCV tend to ignore my good points

SD

D

A

SA

39. People seem afraid o f me once they learn 1 have HCV

SD

D

A

SA

40. When people learn you have HCV, they look for flaws in your character

SD

D

A

SA

Please, stop here!

Thank you,
for taking the time to
complete the HCV Stigma survey!
3
$ Barbara Berger 1996 (Berger’s HIV Stigma Scale modified with permission)
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Today’s D ate: / 2012 / 2013
_

ID Code # ___________________________

Personal Data Collection
Script Thank you for agreeing to participate. I am going to limit (ha amount of time I spend on
each question. If there is a question that you are unsure about or want more information on, we
can discuss it at the conclusion of our session. I have provided RESPONSE CARDS to alow you
to answer the questions.
Instructions: P lease respond to the following questions, in order to better understand you and the
impact your life experience and health history. Your re sp o n se s will remain confidential so p lease
do your b est to answ er each question to th e b e st of your ability.
KEY: The answ er choice “DK / R e f m ean s Don't Know or R efused to answ er

PATIENT DEMOGRAPHICS:
1.

W hat is your G en d er?
□ Fem ale (1)

Q If Other, p le ase sp ecify :____________ (3)

□ Male (2)

2.

W hat is your A ge?

3.

W hat is your R a ce / E th n icity ? (Check all that apply)

___________________ A ge in y ea rs

□ DK / Ref (9)

3a. Alaska Native

4.

Y es

No DK/Ref

1

2

3b. American Indian

9

1

2

9

3c. Asian

1

2

9

3d. Black or African American

1

2

9

3e. Hispanic or Latino

1

2

9

3f. Mexican or Mexican American

1

2

9

3g. Native Hawaiian / Pacific islander

1

2

9

3h. White or C aucasian

1

2

9

3i. If Other. Dlease specify:

1

2

9

Which L an g u a g e do you u se m ost often?
□ My native / tribal la n g u a g e :__________________________________ (1)
□ English (2)
□ S panish (3)
□ If Other, please sp ecify :_____________________________________ (4)
□ D K /R e f (9)

Please, continue to next pagel

1
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I 2012 / 2013

Today’s Data:

ID C o d e #

Personal Data Collection
5.

Do you currently Reside I Live on American Indian reservation / land?
□ Y es (1)

6.

□ No (2)

□ DK / Ref (9)

W hat is your current Marital Status? (Circle one)
□ Single / Never married (1)
□ Married / P artnered (2)
□ Divorced / S eparated (3)
□ Widowed (4)

7.

Do you currently have a Primary Partner? A primary partner is someone with whom you
love more than anyone else and feel a unique commitment?
Q D K /R e f (9)
G Yes (1)
Q No (2)

(If no, Skip question #8 and 9)
8.

Is your Primary Partner som eone of th e S am e sex, O pposite sex, or Both?

9.

Do you currently Live with your husband, wife, primary partner, or significant other?

10.

W hat is the Highest Level of formal education you com pleted or th e highest d eg re e you
have received?
□ Never attended school (1)

□ S am e se x (1)

G Yes (1)

G

O O pposite se x (2) □ Both s e x e s (3)

G

Q No (2)

Q DK / Ref (9)

DK / Ref (9)

G rades 1 through 8 (Elementary) (2)

□ G rades 9 through 11 (Som e high school) (3)
□ G rade 12 (High school graduate) (4)
□ GED (5)
□ Som e college, no d eg ree (6)
□ AA degree (7)
□ BA, BS d eg ree (8)
□ Som e g raduate or professional school (9)

G

G raduate or professional d eg ree (10) Specify d e g re e :______________________

Please, continue to next page!
2

ID Code #

_

Today’s D ate:__________/ 2012 / 2013

Personal Data Collection
11.

What is your O ccupational status?
□ Full-time outside the home (1)
□ Full-time in the home (2)
□ Part-time outside the home (3)
□ Student (4)
□ Retired (5)
□ Volunteer (6)
□ Unable to work / Unemployed (7)

G
12.

Disabled / Handicapped (8)

Which of the following C ategories best describes vour present or most recent job or
occupation?
□ Professional / Administrative (1)

G Clerical, Administrative Support, S ales or Marketing (2)
Q Crafts, Trades, Factory Work, Retail Sales, or Labor (3)
Q Military (4)
Q Casino (5)
G If Other, please specify:_________________________________________ (6)
G D K /R e f(9)
13.

Which category best describes your Total Y early Incom e of ALL members of your
household?
□

$0 - $

10 ,00 0 ( 1)

Q $10,001 to $20,000 (2)
Q $20,001 to $30,000 (3)
Q $30,001 to $40,000 (4)
G $40,001 to $50,000 (5)
G $50,001 to $75,000 (6)
Q $75,001 to $100,000 (7)
Q $100,001 to $150,000 (8)
G Greater than $150,000 (10)
G D K /R e f(9)

Please, continue to next pagel
3
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Today’s D ate:__________ 1 2012 / 2013

ID Code # _____________

Personal Data Collection
14.

Have you ever served in the U.S. Armed Forces? Active duty includes serving in the U.S.
Armed Forces as well a s activation from the Reserves or National Guard.
□ Yes, on active duty in the p a st but not now (1)
□ Yes, now on active duty (2)
□ No, never on active duty except for initial/basic training (3)
□ No,

never served in the U.S. Armed Forces (4)
(If Never Served, Skip question #15)

15.

In which branch or branches did you serve on active duty? (Check all that apply)
O A rm y (1)
□ Navy (2)
□ Air Force (3)
□ Marine Corps (4)
□ Coast Guard (5)
□ Other (e.g., Public Health Service, Environmental Services Administration,
National Oceanic and Atmospheric Administration, U.S. Merchant Marine) (6)

16.

How easy is it for you to Afford (access) medical treatment for Hepatitis C?
□ Very easy (1)
□ Somewhat easy (2)
□ Somewhat difficult (3)
□ Very difficult (4)

17.

This DOES NOT include Indian Health Service, IHS or tribal clinics or doctors where
uninsured patients are charged according to their income. Do you have any type of health
care coverage other than Indian Health Service? (check all that apply)
□ VA (Dept, of Veterans Affairs, CHAMPUS, CHAMPVA, TRICARE (Military) (1)
□ County Services (2)
□ Arizona Health Care Cost Containment System (Medicaid) (3)
□ Medicare, including Medigap supplement (4)
□ Out of pocket by you or your family (copayment) (5)
□ Private insurance purchased directly or by a family member, through a union, or
from a current or former employer (6)
□ No other coverage (7)
□ If Other source, please specify:____________________________ (8)
□ D K /R ef (9)
Please, continue to next page!
4
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ID C ode # ______________

T o d ay ’* D a te :__________ / 2 0 1 2 /2 0 1 3

Personal Data Collection
18.

W hat T re atm en ts have you rec eiv e d for Hepatitis C ? P lea se check all th at apply
□ American Indian T raditional Healing / C e rem o n ial Practices (1)
18a. W hat k in d (s)?______________________________________
18b. When w as th e m ost tre a tm e n t? ______________________
18c. For how lo n g ? _____________________________________
G C o m plem en tary and A ltern ativ e Medicine therapy (2)
For MMnpt*: acupuncture, healing touch. Reiki, yoga, biofeedback, hypnosis, meditation,
chiropractic, and massage

18d. W hat kind(s)?

_____________________________

18e. When w a s th e m ost tre a tm e n t? __________________________________
18f. For how lo n g ? __________________________________________________
□ C om bined HCV Injection / Medication therapy (3)
18g. W hat k in d (s)?__________________________________________________
18h. W hen w as th e m ost tre a tm e n t? __________________________________
181. For how lo n g ? __________________________________________________
□ HCV Injection therapy only i.e.. Interferon (4)
18J. W hat k in d (s)?___________________________________________________
18k. W hen w as th e m ost tre a tm e n t? __________________________________
181. For how lo n g ? __________________________________________________
□ HCV M edication therapy only i.e., Ribavirin, Telaprevir, Boceprevir (5)
18m . W hat k in d (s)?_________________________________________________
18n. W hen w as th e m ost tre a tm e n t? __________________________________
18o. For how lo n g ? __________________________________________________
□ Surgery / O rgan T ra n sp la n t (6)
18p. W hat k in d (s)?__________________________________________________
18q. W hen w as th e m ost tre a tm e n t? __________________________________
18r. For how lo n g ? __________________________________________________
□ No tre a tm e n t (7)
1 8s. Tell m e why you opt NO tre a tm e n t? ______________________________
18L How do you feel about tre a tm e n t? ____________________________ _
18u. Tell m e your cultural beliefs ab o u t treatm ent?
□ D K /R e f (9)
5

__________________
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ID C ode # ____________ __

T o d ay ’* D ate:

7 2 0 1 2 /2 0 1 3

Personal Data Collection
N o te s:________________________________________________________________________________
W hat

When
Where
Why/How
19.

What w as the reason for your Hepatitis C Testing: (check all that apply)
□ Screening of Asymptomatic Patient with No Risk Factors (1)
□ Screening of Asymptomatic Patient with Risk Factors (2)
O Blood / O rgan Donor Screening (3)
□ Evaluation of Elevated Liver E nzym es (4)
□ Follow-up Testing for Previous Marker of Viral Hepatitis (5)
□ Prenatal Screening (6)
□ Sym ptom s of Acute Hepatitis (7)
□ If Other, p lease sp ecify :___________________________________________ (8)
□ D K /R e f (9)

20.

Did you experience any HCV signs/sym ptom s?
20a. Abdominal Pain

□ Y es(1 )

□ No (2)

20b. Arthralgia

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20c. Clay Colored Stool

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20d. Dark Urine

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20e. Diarrhea

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20f. Fatigue

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20g. Fever

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20h. Jaundice

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20i. Loss of Appetite

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20j. N ausea

□ Y es (1)

□ No (2)

□ D K /R e f (9)

20k. Vomiting

□ Y es (1)

□ No (2)

□ D K /R e f (9)

6

□ D K /R e f (9)

141

ID Code # ______________

T o d ay ’s D a te :__________ / 2012 / 2013

Personal Data Collection
PATIENT HEALTH INFORMATION / HISTORY:
During the 2 weeks - 6 months prior to on set of sym ptom s
21 .

W ere you a Contact of a person with Confirmed or Suspected A cute or Chronic HCV
infection?
Acute infection > having HCV infection tor < • months. Chronic infection * having HCV infection for > • months.

□ Y es(1 )

□ No (2)

□ D K /R e f (9)

21a. If yes, w as th e Contact thru: (check all th at apply)
□ B lo o d / O rgan Donation (1)

□ H o u s e h o ld M em ber (non-sexual) (2)

□ in jectio n Drug U se (3)

□ C o n tra c te d d u e to being hospitalized (4)

□ O ccu p atio n al exposure (5)

□ HCV m other transm its to baby (6)

□ S e x u a l / Intimate P artner (7)

Q lf Other, p le ase sp ecify_____________ (8)

□ D K /R e f (9)

22.

In the 6 months before symptom on set (regardless of gender / sexual preference)
0
1
2-6
>6
Unk
22a. How many Male se x partners did you h av e?

D (1 ) 0 ( 2 )

0 (3 )

0 (4 ) 0 5 )

22b. How many Female sex partners did you h av e? 0 ( 1 ) 0 ( 2 )

D (3 )

Q (4 ) 0 ( 5 )

22c. During those last 6 months, how m any of th o se se x partners did you find through th e
Internet? _________________(Total #)

During the 2 weeks - 6 months prior to on set of sym ptom s
23.

Have you EVER been treated for a Sexually Transmitted Disease/Infection?
□ Y es (1)
□ No (2)
□ DK / Ref (9)

23a. If yes, p lease specify type(s): (check all th at apply)
□ Bacterial V aginosis (BV) (1)

□ Chlamydia (2)

□ G onorrhea (3)

□ HepA Virus (4)

□ HepB Virus (5)

□ H epC Virus (6)

□ H erpes, Genital (7)

□ HIV / AIDS (8)

□ Human Papillomavirus (HPV) / Genital W arts (10)
□ Pelvic Inflammatory D isease (PID) (11)
Q Syphilis (12)

□ Trichom onas (13)

□ Vaginitis (14)

□ D K /R e f (9)

23b. Year of m ost recent specified tre a tm e n t? _________________________
Please, continue to next page!
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ID C ode # ______________

T o d ay ’s D a te :__________ / 2 0 1 2 / 2013

Personal Data Collection
24.

Have you EVER used Street Drugs? (Sm oked crack; Snorted meth, Injected cocaine)
□ Y es (1)
□ No (2)
□ D K /R e f (9)

25.

Have you EVER used or sh ared a Needle or Syringe to Inject Drugs intravenously not
prescribed by a health care w orker? (Even once)
□ Y es (1)
□ No (2)
□ DK / Ref (9)

26.

Have you EVER used or sh ared Equipment to Inject Drugs intravenously not prescribed
by a health care worker? (Even once) (Reusing water, bottle cap s, spoons, other
containers, cotton or cigarette filters)
□ Y es (1)
□ No (2)
D D K / R e f (9)

27.

Has a Medical Doctor ev er d iagnosed
□ Yes (1)
□ No (2)

you with Diabetes Mellitus?
□ DK / Ref (9)

27a. If y es, have you sh a re d your diabetic supplies i.e., finger lan cets / syringes?
□ Y es (1)
28.

30.

31.

D D K /R e f (9)

Did you EVER have an Accidental Stick or Puncture with a n eed le or oth er object
contaminated with blood?
□ Y es (1)

29.

□ No (2)

□ No (2)

D D K / R e f (9)

Have you EVER undergone / received long-term kidney Hemodialysis (a m achine that
rem oves certain w aste and chem icals in th e blood w hen your kidney is badly injured)?
□ Y es (1)
□ No (2)
□
DK / Ref (9)

29a. If yes, Month and Year of hem odialysis:__________________________
Have you EVER received Blood / blood products [Transfusion] before July 1M2? (i.e.,
caesarean section, maternal-child transm ission, cardiac surgery)
□ Y es (1)
□ No (2)
□
DK / Ref (9)
30a. If yes, date of tran sfu sio n ?______________________________________
Did you EVER reoeive any Outpatient IV Infusions and/or Injections? (Outpatient
Infusion centers provide intravenous infusions for antimicrobial therapy, therapeutic
injections, i.e., IV antibiotics, fluid/electrolyte m anagem ent, chem otherapy, or medication
infusion therapy and allowing you to not b e hospitalized)
□ Y es (1)
□ No (2)
□
DK / Ref (9)

Please, continue to next pagel
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ID C ode # ______________

T o d ay ’* D a te :__________ / 2 0 1 2 /2 0 1 3

Personal Data Collection
32.

Have you EVER been in C o n ta c t with a P e r s o n ’s blood that had Hepatitis?
□ Y es (1)
□ No (2)
□ DK / Ref (9)
32a. If y es, w as th e C o n ta c t (check all that apply)
□ B lo o d / Organ Donation (1)
□ H o u s e h o ld M ember (non-sexual) (2)
□ in je ctio n Drug U se (3)

□ C o n tra c te d d u e to being hospitalized (4)

□ O ccup atio n al exposure (5)

□ HCV m other transm its to baby (6)

□ S e x u a l / Intimate Partner (7)

O f Other, p le ase sp ecify _____________ (8)

□ D K /R e f (9)
33.

Have you EVER been E x p o se d (visible o r not) to so m eo n e e lse 's blood that had Hepatitis?
□ Y es (1)
□ No (2)
□ DK / Ref (9)
33a. If y es, w as the C o n ta c t (check all that apply)
□ B lo o d / Organ Donation (1)
□ H o u s e h o ld M em ber (non-sexual) (2)
□ in jectio n Drug U se (3)

□ C o n tra c te d du e to being hospitalized (4)

□ O ccup atio n al exposure (5)

□ HCV m other transm its to baby (6)

□ S e x u a l / Intimate Partner (7)

O f Other, p le ase sp ecify _____________ (8)

□ D K /R e f (9)
34.

W ere you EVER em p lo y ed in a M edical or D ental field involving d ire c t c o n ta c t /
e x p o s u re mucosally (eye splash, nose, m ucous m em branes) or to non-intact skin with
human blood or infected n eed les?
□ Y es (1)
□ No (2)
□ DK / Ref (9)
34a. If y e s, w hat w as the frequency of th e direct blood contact / ex p o su re?
□ Frequent (several tim es weekly) (1)
□ Infrequent (2)

35.

W ere you EVER employed a s a P u b lic S a fe ty / E m e rg e n cy W orker having d ire c t
c o n ta c t / e x p o s u re mucosally (eye splash, nose, m ucous m em branes) or to non-intact
skin with human blood or infected n eed les?
□ Y es (1)
□ No (2)
□ DK / Ref (9)
36a. If y e s, p le ase specify:
□ Prison / Jail / Juvenile Facility (1)
□ Fire Fighter (2)
□ Law Enforcem ent Officer (3)
□ If Other, p lease sp ecify :_________________ (4)
36b. If y e s, w hat w as th e frequency of th e direct blood contact?
□ Frequent (several tim es weekly) (1)
□ Infrequent (2)
Please, continue to next pagel
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ID Code # _ _ _ _ _ _ _

T o d ay ’s D a te :________

/ 2012 / 2013

Personal Data Collection
36.

W ere you EVER a resident of a L ong-T erm C a re F acility (i.e., Skill Nursing Facility)?
□ Y es (1)
□
No(2)
□ DK / Ref (9)

37.

W ere you EVER a resident of an In p atien t D rug T re a tm e n t P ro g ra m ?

38.

W ere you EVER a resident of a Halfw ay H o u se ?

□ Y es (1)

□ Y es (1)
39.

□

□

No(2)

□

No(2)

DK / R ef (9)

□

DK / Ref (9)

□

DK / Ref (9)

Have you EVER been In c a rc e ra te d ?
□ Y es (1)

□

No(2)

39a. If y e s , w hat type of facility?
□ Prison (1)

□ Jail (2)

□ Juvenile Facility (3)

39b. If y e s , what year w as th e m ost recent in carceratio n ?_______________
39c. For how lo n g ? ___________________
40.

Did you EVER receive a T atto o (s)?
□ Y es (1)

□

No(2)

□

DK / Ref (9)

40a. If y e s , w here did you receive your tatto o ? (check all that apply)
□ Commercial Parlor / S h o p (1)
□ Prison / Jail / Juvenile Facility (2)
□ If Other, p lease sp ecify :________________________ (3)
41.

Did you EVER have any part of your B ody P ie rc e d (other th an your e a r)?
□ Y es (1)
□ No (2)
D D K / R e f (9)
41a. If y e s , w here did you receive your body piercing? (Check all that apply)
□ Commercial Parlor / S h o p (1)
□ Prison / Jail / Juvenile Facility (2)
□ If Other, p lease sp ecify :________________________ (3)

42.

Have you EVER been diagnosed an d / o r treated by a Medical Doctor for H em ophilia?
Hemophilia is a rare bleeding disorder in which your blood d o esn 't clot normally an d you
may bleed for a longer time than others after an injury. This bleeding can d am ag e your
organs and tissu es and may b e life threatening.
□ Y es (1)
□ No (2)
□ DK / Ref (9)
42a. If y e s , specify year:
_______________ __________

Please, continue to next page!
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Today’s D ate: __________ 12012 / 2013

ID C ode # ______________

Personal Data Collection
43.

44.
45.

46.

H ave you EVER received blood clotting factor co n cen trates produced before 1997 in
order to treat your Hemophilia blood disorder. Before 1987, m ost clotting factors w ere
m ade from hum an blood can carry the viruses th at c a u se HIV/AIDS and Hepatitis. The
main treatm ent for hemophilia is called replacem ent therapy (co n cen trates of clotting
factor)
□ Y es (1)
□ No (2)
□ DK / R ef (9)
43a. If yes, specify y e a r:______________________________ _______________
Did you EVER have Dental work o r Oral Surgery prior to your Hepatitis C diagnosis?
□ Y es (1)
□ No (2)
□ DK / Ref (9)
Did you EVER have Surgery (other than oral) prior to your Hepatitis C diagnosis?
□ Y e s(1 )
□ No (2)
□ D K /R e f (9)
H ave you EVER received a solid organ transplant before July 1992?
□ Y es (1)
□ No (2)
□ DK / Ref (9)
46a. (Organ ty p e )____________________
46b. (Enter year)
_________ _______

Please, stop here!

This concludes th is section. Thank you for taking th e
tim e to com plete th e P ersonal Data Collection survey!
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Appendix U

Today’s Date:

ID C o d e#

/2 0 1 2 /2 0 1 3

Clinical Data Collection
instructions: C lin ic a l d a ta w ill b e c o lle c te d fro m y o u r M e d ic a l R e c o r d , in order to
better understand you and your Hepatitis C illness. Your health information will not link your name
or medical record number. Thank you.
KEY: The answer choice “DK / R e f m eans Don't Know or Refused to answer
CLINICAL A N D D IA G N O STIC DATA:
1.

R eason for Hepatitis C Testing: (check all that apply)
□ Screening of Asymptomatic Patient with No Risk F actors (1)
□ Screening of Asymptomatic Patient with Risk Factors (2)
□ Blood / O rgan Donor Screening (3)
□ Evaluation of Elevated Liver Enzym es (4)
□ Follow-up Testing for Previous M arker of Viral Hepatitis (5)
□ Prenatal Screening (6)
□ Symptoms of Acute Hepatitis (7)

□ Other (specify)_____________________________________________ (8)
□ D K /R ef (9)
CLINICAL DATA I SY M PT O M S:
2.

Hepatitis C diagnosis date: _

3.

Is Patient Sym ptom atic?

/

/

□ Yes (1)

□ No (2)

□ D K /R ef (9)

□ No (2)

□ D K /R ef (9)

□ No (2)

□ D K /R ef (9)

3a. If y es, onset d a te :_________ /
4.

Is / w as P atient hospitalized?

O Yes (1)

4a. Adm D ate:______________________
4b. D/C Date:
5.

________________

Is Patient currently P regnant? D Y e s f l )

5a. Date of D elivery:______________________________

1
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ID C o d e # ______________

T o d ay ’s D ate;

/ 2012 / 2013

Clinical Data Collection
6.

Did th e p a tien t ex p e r ie n c e ? (A n sw er fo r e a c h sy m p to m b elo w )

6a. Abdominal Pain

□ Yes (1)

□ No (2)

□ D K /R e f (9)

6b. Arthralgia

□ Yes (1)

□ No (2)

□ D K /R e f (9)

6c. Clay Colored Stool

□ Y es(1 )

□ No (2)

□ D K /R e f (9)

6d. Dark Urine

□ Y es (1)

□ No (2)

□ D K /R e f (9)

6 e Diarrhea

□ Y es(1 )

□ No (2)

□ D K /R e f (9)

6f. Fatigue

□ Y es (1)

□ No (2)

□ D K /R e f (9)

6g. Fever

□ Yes (1)

□ No (2)

□ D K /R e f (9)

6h. Jaundice

□ Y es(1 )

□ No (2)

□ D K /R e f (9)

61. Loss of Appetite

□ Y es(1 )

□ No (2)

□ D K /R e f (9)

6j. N ausea

□ Y es(1 )

□ No (2)

□ D K /R e f (9)

6k. Vomiting

□ Yes (1)

□ No (2)

□ D K /R e f (9)

VACCINATION HISTORY:
7.

Has participant ever received H epatitis A vaccine?
□ Yes(1)

□ No (2)

7a. If yes, how many doses?

□ DK / Ref (9)
□ 1 dose (1)

□ z2 doses (2)

7b. L ast Hepatitis A d o se (year):______________________
8.

Has participant ever received H epatitis B vaccine?
□ Yes (1)

□ DK I Ref (9)

□ No(2)

8a. If yes, how many doses?

□ 1 dose (1)

□ 2 doses (2)

□ 3+ doses (3)

8b. L ast Hepatitis B d o se (year):______________________
9.

Was participant ever given bnm une Globulin?
□ Yes (1)

□ No (2)

□ D K /R ef (9)

9a. If yes, m onth/year last dose received?_________I
10.___Date when (1st) blood drawn for Hepa titis B foa lin g ? _____________________
10a. Reporting L aboratory:_______________________________________
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T o d ay ’s D ate:

ID C o d e #

/ 2012 / 2013

Clinical Data Collection
DIAGNOSTIC TESTS:
11 .

HAV / HBV / HCV serology results: (check all that apply)
11a. Total Antibody, Hepatitis A Virus {total anti-HAV]
□ Positive (0)

Q Negative (1)

Q

Not Done (2)

□ DK / Ref (9)

11b. IgM Antibody, Hepatitis A Virus PgM anti-HAV]
□ Positive (0)

□

Negative (1)

□

Not Done (2)

□ D K /R e f (9)

Q

Not Done (2)

□ DK / Ref (9)

11c. Hepatitis B Surface Antigen (HBsAg]
□ Positive (0)

□

Negative (1)

11d. Total Antibody, He pa this B Core Antigen [total anti-HBc]
□ Positive (0)

□

Negative (1)

□

Not Done (2)

□ D K /R e f (9)

11e. IgM Antibody, Hepatitis B Core Antigen PgM anti-HBc]
□ Positive (0)

□

Negative (1)

□

Not D one (2)

□ DK / R ef (9)

Not D one (2)

□ DK / Ref (9)

11f. Supplemental Anti-HCV a ssay [e.g., RIBA]
□ Positive (0)

□

Negative (1)

□

Negative (1)

□ Not D one

11g. HCV RNA [e.g., PCR]
□ Positive (0)

□

(2)

□ DK / Ref (9)

(2)

□ D K /R e f (9)

11h. Antibody to Hepatitis C Virus [anti-HCV]
□ Positive (0)

□

Negative (1)

□ Not D one

11i. anti - HCV signal to cut-off ratio______________
Liver E nzym e V alues:
1 2 a .b .c .

S 6 P T (ALT)___

13.a.b.c.

SGOT (AST)

14.

Other te st(s) i.e.. Abdominal U/S

. T est d a te :

/_

U pper limit normal:

T est d a te :

/

U pper limit normal:

G enotype
Transplant List
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